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Ridhi Tariyal, MBA, SM; Hugh S. Taylor, MD; Gu¨nter P. Wagner, PhD; Linda G. Griffith, PhDWomen’s health concerns are generally underrepresented in basic and translational research, but reproductive health in particular has been
hampered by a lack of understanding of basic uterine and menstrual physiology. Menstrual health is an integral part of overall health because
betweenmenarche andmenopause, most womenmenstruate. Yet for tens of millions of women around the world, menstruation regularly and
often catastrophically disrupts their physical, mental, and social well-being. Enhancing our understanding of the underlying phenomena
involved in menstruation, abnormal uterine bleeding, and other menstruation-related disorders will move us closer to the goal of personalized
care. Furthermore, a deeper mechanistic understanding of menstruation—a fast, scarless healing process in healthy individuals—will likely
yield insights into a myriad of other diseases involving regulation of vascular function locally and systemically. We also recognize that many
women now delay pregnancy and that there is an increasing desire for fertility and uterine preservation. In September 2018, the Gynecologic
Health and Disease Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development convened a 2-day
meeting, “Menstruation: Science and Society” with an aim to “identify gaps and opportunities in menstruation science and to raise
awareness of the need formore research in this field.” Experts in fields ranging from the evolutionary role of menstruation to basic endometrial
biology (including omic analysis of the endometrium, stem cells and tissue engineering of the endometrium, endometrial microbiome, and
abnormal uterine bleeding and fibroids) and translational medicine (imaging and sampling modalities, patient-focused analysis of menstrual
disorders including abnormal uterine bleeding, smart technologies or applications andmobile health platforms) to societal challenges in health
literacy and dissemination frameworks across different economic and cultural landscapes shared current state-of-the-art and future vision,
incorporating the patient voice at the launch of the meeting. Here, we provide an enhanced meeting report with extensive up-to-date (as of
submission) context, capturing the spectrum from how the basic processes of menstruation commence in response to progesterone with-
drawal, through the role of tissue-resident and circulating stem and progenitor cells in monthly regeneration—and current gaps in knowledge
on how dysregulation leads to abnormal uterine bleeding and other menstruation-related disorders such as adenomyosis, endometriosis, and
fibroids—to the clinical challenges in diagnostics, treatment, and patient and societal education. We conclude with an overview of how the
global agenda concerning menstruation, and specifically menstrual health and hygiene, are gaining momentum, ranging from increasing
investment in addressing menstruation-related barriers facing girls in schools in low- to middle-income countries to the more recent
“menstrual equity” and “period poverty” movements spreading across high-income countries.
Key words: abnormal uterine bleeding, adenomyosis, endometrium, fibroids, menstrual health, microbiome, pelvic health menstrual
effluent, period poverty, stem cells, tissue engineering, uterusIntroduction
Twenty-five years have passed since the
National Institutes of Health (NIH)
mandated that women andminorities be
included in all government-funded
clinical studies unless their exclusion
could be justified. Clearly, this policy has
led to numerous women’s health
research programs. However, women
and women’s health concerns continue
to be underrepresented in research.Most
recently, the 2019e2023 Trans-NIH
Strategic Plan for Women’s Health
Research was initiated to improve the
health of women by advancing rigorous
research relevant to advancing women’s
health, including sexual and reproduc-
tive health (SRH). Despite focusedinitiatives such as these, diagnostic
development for improving women’s
reproductive health has been hampered
by a lack of understanding of basic
uterine and menstrual physiology. A
PubMed search of the term “menstrua-
tion” yielded less the 1000 publications
between 1941 and 1950, followed by a
peak of more than 6000 publications
between 1971 and 1980 (note: Our
Bodies, Ourselves, a book addressing
women’s health topics, including
menstruation and birth control, was
published in 1973), and then a stable
trough with less the 4000 publications
per decade over the past 3 decades
spanning 1991 through 2019 (Figure 1,
A). By contrast, a PubMed search of theMONTH 2020term “menstrual blood” yielded 1 pub-
lication during 1941e1950, followed by
a steady increase over time to more than
400 publications in the last decade
(Figure 1, B). For reference, PubMed
searches of “peripheral blood” and
“semen” yielded almost 100,000 and
15,000 publications, respectively, over
the past decade.
In September 2018, the Gynecologic
Health and Disease Branch (GHDB) of
the Eunice Kennedy Shriver National
Institute of Child Health and Human
Development (NICHD) convened a 2-
day meeting to “identify gaps and op-
portunities in menstruation science and
to raise awareness of the need for moreAmerican Journal of Obstetrics& Gynecology 1
Expert Review ajog.orgresearch in this field.” Leaders in the field
with expertise in endometrial biology,
omic analysis of the endometrium and
menstrual effluent, new imaging or
sampling modalities, smart technologies
or applications (apps) and mobile health
(mHealth) platforms, menstrual health,
and health literacy and dissemination
frameworks were invited to participate
as speakers and discussants to critique
and summarize new discoveries and av-
enues of future research surrounding
menstruation. This meeting encom-
passed normal menstrual health and
endometrial function and the potential
of diagnostics for abnormal functioning
and disease. To provide a broad
perspective on menstruation science,
this meeting included investigators and
stakeholders across multiple disciplines,
including population health and public
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I. Introduction
According to the World Health Organi-
zation, “health” is “a state of complete
physical, mental and social well-being and
not merely the absence of disease or
infirmity.”1 For women, menstrual health
is an integral part of overall health because,
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ONTH 2020women menstruate and menstruation can
have a significant impact on the physical,
mental, and social well-being.2 Normal
menstruation is currently defined as cyclic
bleeding that occurs from the uterine
corpus between menarche and meno-
pause. It can be described in terms of 4
simple domains: how frequently the
woman has episodes of bleeding, the reg-
ularity or predictability of these episodes,
the duration of bleeding episodes, and the
volume or heaviness of bleeding.3e5 Not
all women experience “normal”menstrual
bleeding; up to 30% of women will expe-
rience alterations in the volume or pattern
of menstrual blood flow, which is defined
as the symptom of abnormal uterine
bleeding (AUB), which in turn can be
caused by multiple etiologies and some-
times more than 1 etiology at the same
time.3,6 In addition, many women will
have other symptoms such as pain,ed Kingdom (Drs Critchley and Maybin);
ago, IL (Drs Babayev and Bulun); Days for Girls,
INCLIVA, Valencia, Spain (Ms Garcia-Grau, Dr
iversity of Valencia, Valencia, Spain (Ms Garcia-
Gregersen andDrMetz); Massachusetts General
(Dr Kim); Below your Belt Health, Chicago, IL (Ms
logy, University of Michigan Medical School, Ann
fants Hospital, Warren Alpert Medical School of
e, Newark, DE (Dr Silk); Department of
mer); Beth Israel Deaconess Medical Center,
of Medicine, Houston, TX (Dr Simon); NextGen
School of Medicine, NewHaven, CT (Dr Taylor);
ctive Sciences, Systems Biology Institute, Yale
ersity, Detroit, MI (Dr Wagner); and Center for
des consultancy advice (but with no personal
ant Sciences GmbH. H.O.D.C. receives royalties
rs Kluwer for work on the topic
re longitudinal research study and clinical trial (all
ntific advisor for Myovant (advises on patient
tion). K.A.M. has received honoraria fromABOG,
airs Title X Grant Reviewer (received honorarium).
uthors report no conflict of interest.
000066, G0500047, G0600048, MR/J003611/
6/52). This work has been supported by the NIH
EACH), Center for Biotechnology’s NIH award
the National Institutes of Health-Award Number
CATS UG3 (ES029073) and NIH/NCI
ciences (SGCL13). G.P.W. is a recipient of John
HU01EB029132-01, The John and Karine Begg
riverNational Institute of Child Health and Human
cense (http://creativecommons.org/licenses/by-nc-nd/
FIGURE 1
PubMed publications, 1941e2018
A, Search term “Menstruation.” B, Search term “Menstrual Blood.”.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
ajog.org Expert Reviewdysmenorrhea, anxiety, depression, and
fatigue associated with their menstrual
cycle that require attention for them to
achieve early diagnosis of reproductive
health issues such as endometriosis, pre-
menstrual syndrome, and premenstrual
dysphoric disorder and attain optimal
health. In research and in clinical care, a
better understanding of what the norms
of menstrual health are and how a “lack”
of menstrual health affects women’s
quality of life is needed. Furthermore, for
positive health and well-being outcomes,
everyone—men and women, as well as
clinicians—need to understand men-
strual cycles and menstrual health, which
can be achieved through menstrual
health literacy initiatives and improved
health communication.
Menstrual health andmenstrual health
literacy are extremely broad topics with
multiple stakeholders and diverse areas of
active investigation and contributors.
Adapted from the broader health literacy
definition, menstrual health literacy re-
fers to the level of capacity a person has to
obtain, process, and understand basic
information about menstruation so they
can make appropriate health decisions.7
This section of the manuscript summa-
rizes the presentations and discussion
that took place related to menstrual
health andmenstrual health literacy at the
2018 “Menstruation: Science and Soci-
ety” meeting hosted by the GHDB of the
NICHD. We summarize only areas of
menstrual health and literacy that werepart of the presentations and active dis-
cussions at the NICHD GHDB meeting,
which were largely focused on the
bleeding aspect of menstrual health.
II. Progress in menstrual health
terminology and menstrual health
literacy and communication
Progress in menstrual health terminolo-
gy. Standard terminologies related to
menstrual bleeding, and specifically
AUB, represent real progress for clinical
care and research. Ill-defined terminol-
ogies to describe symptoms, signs, and
diagnoses associated with AUB led to
communication challenges in clinical
care, difficulty interpreting populations
included in published literature, and lost
opportunities for multisite research
collaboration for clinical research on
treatments for AUB.
In 2005, the Menstrual Disorders
Working Group of the International
Federation of Gynecology and Obstetrics
(FIGO) embarked on a worldwide
consensus-building process to generate
and disseminate a simple symptom
description system and a classification
system for the etiologies associated
with AUB.8,9 The first system, “Terminol-
ogies and Definitions,” includes standard
definitions for bleeding symptoms do-
mains,which include regularity, frequency,
duration, and volume.3 The second sys-
tem, “Classification of Causes of AUB in
the Reproductive Years,” commonly
referred to as the polyps/adenomyosis/MONTH 2020leiomyoma/malignancy (PALM)e
coagulopathy/ovulatory/endometrial/iat-
rogenic/not otherwise classified (COEIN)
system, includes a list of etiologies that
can be associated with AUB (polyps,
adenomyosis, leiomyoma, malignancy
and hyperplasia, coagulopathy, ovulatory,
endometrial, iatrogenic, and not other-
wise classified). Results of this work were
published in peer-reviewed publications
andwere used by the American College of
Obstetricians and Gynecologists (ACOG)
during their process standardizing ter-
minologies used across gynecologic spe-
cialties.4,5 ACOG and the members of the
Women’s Health Registry alliance
convened the revitalize Gynecology Data
Definitions initiative in December 2013
to develop standardized data elements
and definitions in gynecology.
Throughout this process, ACOG engaged
a broad range of stakeholders to identify
priority topics and definitions and then
worked with a core group of contributors
to generate a total of 119 data elements,
including 7 pain-related and 7 bleeding-
related definitions.4,5 Although there is
more work to be done in terms of eval-
uating these definitions across diverse
populations of women, these standard-
ized terminologies represent positive first
steps to facilitate research data collection,
collaboration for study participant
recruitment, and identification of study
cohorts with similar etiologies when
investigating the prevalent symptom of
AUB.American Journal of Obstetrics& Gynecology 3
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increased emphasis on the patient expe-
rience of bleeding, quality of life, and
related symptoms associated with the
menstrual cycle in both research and na-
tional guidelines. The National Institute
for Health and Clinical Excellence (NICE)
Clinical Guidelines on Heavy Menstrual
Bleeding (HMB) published a patient-
centric definition of the symptom of
HMB, which they define as “excessive
menstrual blood loss that interferes with a
woman’s physical, social, emotional, and/
or material quality of life.”10 Qualitative
and quantitative research with women to
learn about their experiences with and
knowledge of menstrual bleeding, fibroid-
related symptoms, pain, and other asso-
ciated symptoms has begun to inform
research priorities, educational tools, and
the need for outcome measures for AUB
and uterine fibroids.11e14 Several studies
have suggested that patient-reported
outcome measures (PROMs), which
include standardized interviews, ques-
tionnaires, charts, and surveys that assess
the patient’s own evaluation of her health
and symptoms, are the key to assessing the
impact of illness and symptomatology
among women with reproductive health
issues including AUB.2,15e19
Progress in menstrual health literacy and
communication. There has been recent
progress in the areas of menstrual health
literacy, advocacy, and communication,
in part facilitated by the rapid acceptance
of mHealth apps, the use of mobile
technologies to provide health-related
services (tracking information and
providing information or education to
support an individual’s achievement of
health objectives).20,21 At present, there
are more than 300 reproductive health
mHealth products in the IOS andGoogle
stores, with the majority of the apps
focused on women of childbearing age.
The apps vary in their depth of pelvic
health information, with the majority
including cycle and fertility trackers.
Two of the larger apps as far as global
reach, CLUE and FLO, have expanded
both their tracking (CLUE) or daily no-
tifications and information (FLO) to
include facts or daily tips, which, though
brief, may be useful to assist in4 American Journal of Obstetrics& Gynecology Midentifying women with the symptom of
AUB. Additional data are needed to
better understand the demographics of
and reasons why women use these apps.
III. Significant conceptual, practical, or
technical challenges in the field of
menstrual health research and
menstrual health literacy
The progress in the field of menstrual
health outlined previously is remarkable
given themultiple challenges and obstacles
in the field of menstruation science.
Menstruation is a physiological process
that is experienced almost universally
across cultures from the ages of menarche
to menopause. What makes menstrual
health and menstrual health literacy chal-
lenging to study is that for many, it is a
normal process that is not associated with
any distress or disability, but for some it
can be associated with a significantly
negative impact on the quality of life.
Collecting data on a nearly universal pro-
cess will require collaboration across the
spectrum of disciplines and careful
consideration of “who” to collect data
from, “what” data elements to collect, and
“how” to best collect data. Furthermore,
the normalization of women’s pain and
stigma surrounding menstrual bleeding
and reproductive health represent signifi-
cant barriers to women’s care seeking,
diagnosis, and ability to conduct research
in this area.22 Menstrual health and men-
strual health literacy research is further
complicated by a lack of standardization of
tools and access to those tools, themultiple
different etiologies of HMB, the multidi-
mensional symptom complex surround-
ing bleeding, lack of clear diagnostic tests
for reproductive health disorders that
affectmenstrual health, suboptimal norms
for menstrual health and bleeding across
the life span, and insufficient information
related to cultural perceptions related to
menstrual bleeding and health.
Although awareness of the importance
of patient experience with menstrual
bleeding and menstrual symptoms has
increased in research and clinical care,
sustained reliance on “objective” labora-
tory measures for outcomes related to
menstrual health represents an additional
conceptual barrier to progress in this area.
To provide an AUB-specific example,ONTH 2020traditionally in research, bleeding was
measured by volume of menstrual blood
lost (>80 mL) as measured by the collec-
tion of used sanitary products and quan-
tified using the alkaline hematinmethod.23
However, research has highlighted that
mostwomenwho seek treatment forHMB
do not meet the objective mean blood loss
criteria for heavy bleeding and clinical care
objectively measured blood loss is not
feasible.19 As a result of these studies and
others, NICE, theNationalHealth Services
(NHS) in the United Kingdom, stated in
2018 that “From the woman’s point of
view objective reduction in mean blood
loss are poor indicators of treatment
effectiveness for heavy menstrual
bleeding.”10 This lack of consistency
between what has been prioritized as a
measurement for research and what
women prioritize in terms of desired
outcomes represents a current obstacle
for high-quality research and synergy
between research on HMB, clinical care,
and patient-centered care delivery.
IV. Critical gaps in menstrual health
literacy, advocacy, or communication
and how they can be addressed to
optimize women’s menstrual health
Conceptual, practical, and technical
challenges related to research on men-
strual health and menstrual health liter-
acy and communication have led to
several critical gaps in the evidence base
in this area. During the meeting, several
gaps in the evidence base and opportu-
nities to improve women’s health by
addressing these gaps with high-quality
research were discussed.
Data to inform “norms” that hold across
populations and span from menarche to
menopause. Generation of standard ter-
minologies related to norms for uterine
bleeding among adult women represents
significant progress in the field of men-
strual health, and there has been signif-
icant progress especially in describing
symptom expectations in the later
reproductive life stages and during the
menopausal transition.24e27 To ensure
that menstrual bleeding norms represent
bleeding patterns and other menstrual
health symptoms across a racially and
ethnically diverse and contemporary
ajog.org Expert Reviewpopulation (relative to comorbid con-
ditions and body mass index) of women
of all ages, further research is needed.28
Prospective longitudinal cohort data on
menstrual bleeding, menstrual symp-
toms, and reproductive health diagnoses
could fill this critical gap.
Developments inmHealth could also be
used to inform norms and measure the
personal impact menstruation and men-
strual symptoms have on women across
the life cycle. For population-based data
outside of clinical care, data collected from
mHealth and mobile device apps are
starting to enable the analyses of
population-level longitudinal menstrual
symptom and cycle data.29 In addition,
these mHealth data could facilitate inves-
tigation into cultural differences, knowl-
edge, attitudes, and behaviors. By
partnering with mHealth and app plat-
forms, researchers, clinicians, and industry
could generate data collectionmechanisms
and assist in generating research programs
and interventions that could aid women in
identifying when they are having a prob-
lem and address stigma and perceptions
related to menstrual disorders, delays in
diagnosis of reproductive health disorders,
and delays in care seeking.
Standardizing data collection in research,
clinical care, and mobile health technologies
to promote consistency and optimize
comparative effectiveness research.A shift in
research to focus on measuring patient
experiences with symptoms and chronic
health problems, including reproductive
health and menstrual health issues, rep-
resents significant progress in the arena of
women’s health. However, although there
are several validated PROMs for AUB,
there is no single high-quality PROM that
is considered “standard of care” or “stan-
dard for use across studies.”17,30,31 This
translates into hundreds of outcome
measures, of varying quality, used across
studies and an inability to combine data
across studies to summarize patient
experience. In a systematic review of
patient-reported outcomes used across
studies of AUB, authors found 80 studies
that used at least 1 PROMand 77 different
PROMs were used across studies.31 The
Society of Gynecologic Surgeons, in a
systematic review comparing treatmentsfor HMB, identified that 114 different
outcomes were collected and reported
across 79 distinct clinical trials.17 The end
result was that, because the method of
assessing outcomes differed from study to
study, data could not be combined or
summarized for these outcomes (such as
quality of life and bleeding-related quality
of life), which prohibited the group from
generating consensus on treatment effec-
tiveness relative to patient-reported out-
comes.17 Researchers across disciplines of
menstrual health research have expressed
challenges describing the menstrual
symptom phenotype of patients involved
in clinical research because of a lack of
standardized structured menstrual history
data elements. Finally, discussions at this
meeting also highlighted the importance
of a broader view of menstrual health that
goes beyond bleeding to include other
associated symptoms, which will need
additional research and standardized data
elements.
The research community can collabo-
rate to address this challenge and stan-
dardize outcomes and data elements for
research and quality assessments. For
example, the Core Outcomes in Women’s
and Newborn Health, an international
initiative led by journal editors and is
endorsed by more than 80 peer-reviewed
journals in women’s health, is working to
stimulate the development of outcome sets
that can be used across studies to ensure
consistent outcome reporting, thereby
improving the interpretability of study
results and the feasibility of combining
data across studies.32,33 Efforts to stan-
dardize data elements from a structured
menstrual history describing frequency,
regularity, duration, and patient-
quantified volume of bleeding along with
other associated menstrual symptoms are
needed to facilitate consistent descriptions
of populations in studies on menstrual
health, AUB, uterine fibroids, and other
reproductive health issues.34
V. Additional future directions in
menstrual health research
Transforming comparative effectiveness
research by incorporating patient-reported
outcome measures into electronic health
records. Looking to the future, stan-
dardizing and harnessing the potential ofMONTH 2020patient-based outcomes assessment
could transform comparative effective-
ness research. Emerging technology de-
velopments may be paving the way to
have PROM collection integrated into
electronic health records, which would
promote patient-centered comparative
effectiveness research.35,36 Researchers,
policy makers, and professional societies
are currently working out best practices
for integrating PROMs and electronic
health records.35,36 This integration
could mean substantially greater capa-
bilities for patient-relevant comparative
effectiveness research and health services
research, which often relies on electronic
health record or administrative datasets
that rarely incorporated patient-
reported data elements, particularly on
reproductive health problems that affect
the quality of life.
Incorporating PROM collection into
clinical care encounters may represent
major opportunities to evaluate processes
of healthcare delivery. Future research
opportunities include assessing whether or
not incorporating PROMs into electronic
health records and clinical encounters for
menstrual health disorders can improve
physician-patient interactions and be used
to monitor patient symptoms or progress
over time. On the population level,
incorporating PROMs into clinical care
can assist with clinical care quality assess-
ment and population surveillance. For
example, in the UK NHS, PROMs are
collected before and after certain surgical
interventions to determine the quality of
care delivery and to facilitate counseling
for patients on what to anticipate in terms
of the personal impact of the surgery.37
Partnerships across diverse disciplines and
stakeholder groups. Innovative solutions
to address comprehensive menstrual
health across the life span will require
collaboration across scientific disci-
plines, social science disciplines, and
involvement of patient- and person-
facing organization to ensure the rele-
vance and success of these solutions for
addressing the needs of the population.
Menstrual health research in the future
could be enhanced by developing
collaborative interdisciplinary teams to
investigate comprehensive menstrualAmerican Journal of Obstetrics& Gynecology 5
Expert Review ajog.orghealth premenarche to menopause. In
addition, including patient-facing
groups in study design and beta testing
of programs from the beginning and
partnering with patient groups and
advocacy groups to create and dissemi-
nate communication platforms and
menstrual health educational initiatives
could enhance the fields of menstrual
health, menstrual health literacy, and
menstrual health communication.
VI. Conclusion
Each year, 4.5 million women in the
United States experience at least 1 gy-
necologic health problem, and many of
these problems are related to menstrual
health.6 Although significant progress
has been made in menstrual health
research in terms of emphasizing pa-
tient experience, standardizing termi-
nologies related to menstrual bleeding,
and use of PROMs for menstrual dis-
orders, more work and research are
needed to standardize data collection,
generate longitudinal data on contem-
porary norms of menstrual bleeding
and related symptoms, and optimize
use of new technologies and educa-
tional interventions. Health commu-
nication strategies that are accessible to
groups with low literacy and address
potential stigma associated with
menstruation will help to address bar-
riers as well. Increasing the evidence
base on menstrual health and men-
strual health literacy will aid in the
evolution of contemporary clinical care
that meets the unique needs of women.
Bringing women and advocacy groups
to the table and bringing data collection
and information directly to women
through innovative technologies,
smartphone apps, and mHealth has the
potential to move the field of
menstruation science away from treat-
ing problems and toward optimizing
women’s overall health, and more spe-
cifically menstrual health. Continuing
the recent momentum on patient-
focused menstrual health research to
sustain progress in the field of men-
strual health, literacy, and communi-
cation has the potential to have a
substantial impact on the lives of
women.6 American Journal of Obstetrics& Gynecology M2. The Evolutionary History of
Menstruation
Günter P. Wagner, PhD
Menstruation and its associated diseases
such as HMB and AUB are a significant
burden on women of reproductive age
(see section Menstruation and abnormal
uterine bleeding below), which raises the
question of why women menstruate at
all. This question is particularly perti-
nent given the fact that menstruation is
dispensable for mammalian reproduc-
tion (see below). Answers require a re-
view of the evolutionary history of
mammalian reproduction, given that
humans and great apes, that is, species
that menstruate, evolved from ancestors
that did not menstruate. What are the
advantages menstruation affords
humans and other primates that, from a
biological point of view, could make the
origin and biological role of menstrua-
tion understandable?
I. Menstruation is rare among animals
Menstruation is defined as the shedding
of the upper (the so-called “functionalis”)
layer of the uterine lining after the luteal
phase of the ovarian cycle. Although
menstruation is a normal part of the life
of a woman during her fertile years, it is
only found in a small minority of ani-
mals. Because menstruation is a function
of the female reproductive organs, one
would expect to find menstruation in
animals with a similar mode of repro-
duction as humans, that is, the so-called
placental mammals (technically called
“eutherian mammals”). Eutherian
mammals are all the species that descen-
ded from the most recent common
ancestor of humans and elephants,
meaning all the mammals that we are
most familiar with: apes, monkeys, farm
animals, cats, dogs, seals, hedgehogs, and
others (Figure 2). All of these animals
have a placenta and a gestational period
that is longer than their ovarian cycle, so-
called trans-cyclic gestation,38 with the
exception of animals that have pseudo-
pregnancy in the absence of fertilization,
such as the dog.39
Despite the substantial similarities,
with respect to female reproductive
biology, between humans and all other
eutherian mammals (eg, compared withONTH 2020reptiles and birds), menstruation only
occurs in a small minority of eutherian
species. The largest cluster of menstru-
ating species is found among our closest
relatives, the primates. In particular,
apes, old world monkeys, and most but
not all of new world monkeys have
menstruation. More basally diverging
primate lineages do not (lemurs and
tarsiers, where in the latter conflicting
evidence has been reported, summarized
in the study by Emera et al40). Outside
the primates, menstruating species are
rare. Among the rodents, only one spe-
cies has been described as menstruating:
the spiny mouse, Acomys cahirinus.41
This is surprising, given the large num-
ber of rodent species (2277 species).
Then there is a small number of bat
species belonging to 2 groups of bats, 1
molossid bats and 3 phyllostomid bats.42
Most distantly related menstruating
species to humans is the elephant shrew
(Elephantulus myurus43,44) related to el-
ephants and other afrotherian mam-
mals. These menstruating species add up
to 84 species, or about 1.6% of the 5149
recognized extant eutherian species. This
estimate could be a slight undercount
because it is not easy to diagnose
menstruation in species that have not
been kept in laboratories or zoos and
have been closely monitored.
If we put the menstruating species on
the phylogeny of mammals (Figure 2),
we see a rather dispersed distribution.
Clearly, all the primate species that
menstruate are relatively closely related,
but the spiny mouse, bats, and the
elephant shrew are not. The conclusion
that follows from these facts is that
menstruation must have evolved at least
4 times independently during the
evolutionary history of mammals. This
conclusion is also supported, for
instance, by differences in the exact
location and nature of the endometrial
changes in the elephant shrew (summa-
rized in the study by Carter45). The rarity
and repeated evolution of menstruation
raise the question about its biological
role. Menstruation is clearly not neces-
sary for a mammal because it is rare, but
it might have a specific role, rather being
there accidentally, because it originated
at least 4 times independently.
FIGURE 2
Phylogenetic distribution of menstruating species among eutherian
mammals
Lineages in black are from menstruating species, and lineages in white from nonmenstruating
species. The lineages with red outline are the lineages where menstruation originated. Note that
there are at least 4 independent originations of menstruation.
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question of why some mammals
menstruate and others do not, we should
mention that not every case of vaginal
bleeding by a healthy animal is
menstruation. The best known example
is the vaginal bleeding of the dog, which
is not a sign ofmenstruation.39 Themain
difference between what is happening in
dogs and in menstruating species is that
the vaginal bleeding in dogs happens in
proestrus, that is, in preparation for
mating, rather than after the fertile phase
is over, as it is the case in women. The
bleeding in dogs is caused by extravasa-
tion during the growth of the uterine
lining, which can break through the
epithelium leading to a vaginal efflux.
II. Why did menstruation evolve?
The fact that menstruation plays a major
role in the life of a woman and that it is
rare among animals has inspired many
scientists, anthropologists, and medical
researchers to speculate about its bio-
logical role.46e52 This is not the place to
review all the ideas that have been pro-
posed to explain the evolution of
menstruation but note that the most
honest and shortest answer to this
question is “we do not know.”53 Never-
theless, there has been some progress in
reframing the question that points to two
plausible answers.
An important breakthrough in un-
derstanding the evolution of menstrua-
tion was the realization that
menstruation itself may not be the direct
biological trait that was shaped by nat-
ural selection, but rather that menstru-
ation could be a secondary consequence
of an underlying biological trait: spon-
taneous decidualization.52
Decidualization is the process by which
the uterine lining prepares for pregnancy.
This is a complex process including pro-
liferation of the endometrial stroma, the
traffic of various kinds of white blood cells
into the endometrium, and the differen-
tiation of the endometrial fibroblasts into
so-called decidual stromal cells (DSCs).54
Decidualization in the narrow sense re-
fers to the differentiation of DSC, rather
than to the whole organ-level process. In
most animals, decidualization occurs in
the estrogen- and progesterone-primeduterus in response to the presence of the
embryo. This is induced decidualization.
However, in humans, decidualization oc-
curs even in the absence of an embryo and
is therefore called spontaneous deciduali-
zation. It turns out that all menstruating
species undergo spontaneous decidualiza-
tion,40,41,52 suggesting that the evolved trait
is not menstruation per se, but sponta-
neous decidualization. In humans, it has
been shown that the proximate cause for
menstruation (see section on Menstrua-
tion and abnormal uterine bleeding) is the
decrease in progesterone levels owing to
the degeneration of the corpus luteum. An
experimental model of artificial decidual-
ization in a nonmenstruating species, the
mouse, Mus musculus, shows that in fact
progesterone withdrawal after deciduali-
zation is sufficient to cause menstruation-
like symptoms, that is, degeneration ofMONTH 2020part of the endometrium and vaginal
bleeding.55e58
There are several versions of this
experiment but the cleanest model is the
one published by Rudolph et al56 in 2012:
intact femalemice weremated with sterile,
vasectomized males, which in mice causes
pseudopregnancy, meaning that the fe-
male maintains a high level of progester-
one even though no fetus is developing in
her uterus. After copulation, the pseudo-
pregnant mice were injected with a small
droplet of oil into the lumen of the uterus.
It is known that this treatment causes the
uterine lining of the mouse to decidualize,
leading to a so-called “deciduoma,” which
is a condition that, in many respects,
mimics fetus-induced decidualization.
The key observation of this experiment
then was that as progesterone levels were
decreasing toward the end of theAmerican Journal of Obstetrics& Gynecology 7
FIGURE 3
Schematic outline of the experiment by Rudolph et al56 testing the idea
that menstruation is a secondary consequence of spontaneous
decidualization
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The experiment is conducted with the laboratorymouse, which is a species that under normal conditions is
neither decidualizing nor menstruating. In this species, clitoral or vaginal stimulation during copulation
leads to themaintenance of the corpus luteum even if no pregnancy ensued, leading to pseudopregnancy,
as is the case by copulation with a vasectomized male. Furthermore, it is known that injection of a small
droplet of oil into the uterine lumen causes decidualization. The experiment starts with mating a female to
a vasectomized male to induce a pseudopregnancy. At the morning of the following day, the females are
checked for a copulatory plug to verify that copulation has taken place. Then at day 4 after copulation, a
small droplet of oil is injected into the uterus to induce decidualization. Day 4 is the normal day of im-
plantation in mice. Then the mice are monitored for their level of progesterone and signs of vaginal
bleeding. Progesterone starts to decrease after day 7, and bleeding ensues at about day 9. This
experiment shows that differentiation of the endometrium (decidualization) is sufficient to cause
menstruation-like symptoms in a species that normally does not menstruate.
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This result supports a model according to
which menstruation is an inevitable
consequence of spontaneous decidualiza-
tion if fertilization and pregnancy do not
occur (Figure 3).
Both, the comparative evidence,
namely, the association between
menstruation and spontaneous deciduali-
zation among mammals, and the experi-
mental evidence with artificial
decidualization lead to the conclusion that
the real question thus is not “why some
species menstruate?” but “why do some
species show spontaneous decidualization
and menstruate as a consequence?” There
are 2 plausible answers, but no definite
consensus on this issue has been reached.8 American Journal of Obstetrics& Gynecology MOne model assumes that spontaneous
decidualization is a protective device for
the mother against an aggressive
fetus.40,47,52 This model is based on the
observation that the degree of invasiveness
of the placenta varies between species. This
is even the case among species with so-
called hemochorial placentation, that is,
where the fetus is destroying not only the
uterine luminal epithelium but also some
of the uterine blood vessels so that the
placenta is in direct contact with maternal
blood. For instance, great apes have
extravillous trophoblast cells, which
invade the maternal blood vessels (spiral
arterioles), the stroma, and even the
muscular layer of the uterus (myome-
trium).59 Clinical observations have alsoONTH 2020revealed cases where a placenta embeds
too deeply into the uterus, a condition
called “placenta accreta” or “placenta per-
creta” depending on the depth of invasion.
These conditions can threaten the life of
the mother after birth because of massive
uterine bleeding.60 Finally, one of the roles
of the decidual cells is to both enable and
limit the invasion of the placenta and thus
regulate the depth of implantation even
though the mechanisms are still unclear.
Hence, it seems plausible that spontaneous
decidualization is ensuring that a
conceptus finds an environment that is
prepared to allow and at the same time
limit the degree of placental invasion. To
our knowledge, no formal test of this
model has been attempted. In particular,
one would need a way to measure inva-
siveness of the conceptus in various ani-
mals, many of which are not laboratory
models and thus hard to work with.
Furthermore, we have no information
whether and which close relatives of
menstruating species are also menstru-
ating to test for a correlation between
menstruation and depth of placental
invasion.
The second model to explain the
evolutionary origin of menstruation as-
sumes that spontaneous decidualization
is an adaptation to allow the female to
“test” the viability of the conceptus
before definite pregnancy ensues.61e64
This model is inspired by the observa-
tion that decidual cells have the ability to
sense the vitality of the embryo and react
with a stress reactionwhen the embryo is
of inferior quality. The idea is that this
ability of DSCs helps the mother avoid
investing resources in an ultimately un-
successful pregnancy and thus increases
the reproductive fitness of the female by
allowing her to achieve pregnancy
sooner. This idea is supported by the fact
that humans have a rate of pregnancy
loss of 10% to 25%65 (higher estimates
found in the literature seem to be
spurious) and that spontaneous
decidualization is primarily found in
animals with a small litter size, that is,
one or two neonates per pregnancy and
thus with correspondingly higher in-
vestment into each offspring. The
recently described, yet not fully evalu-
ated, spiny mouse is somewhat an
FIGURE 4
The modern effect of menstruation
Previously, women experienced menstruation approximately 40 times in their lifetime, owing to
pregnancy and lactational amenorrhea. Women may now expect to have more than 400 episodes of
menstruation, mainly as a result of fertility management. Therefore, AUB is increasingly common.
Women may experience significant anemia resulting in a poor physical quality of life. A negative
financial effect occurs because of the cost of managing their blood loss and an inability to work
outside the home. These costs, alongside a loss of caring ability, will have a negative effect on the
wider family. The cost to society through loss of work days and healthcare costs is significant.
AUB, abnormal uterine bleeding.
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2 or 3 but can be as high as 6.41 Again,
there is a dearth of comparative data to
fully test this idea, given that we do not
know the rate of pregnancy loss in most
animals, and whether it is different be-
tween closely related species that differ in
the presence or absence of spontaneous
decidualization.
III. An evolutionary argument for the
validity ofmenstruation as a diagnostic
tool
In a later section, the utility of menstrual
efflux as a diagnostic tool will be dis-
cussed in detail. Here, we review an
evolutionary argument that supports the
idea that menstruation may be predictive
of pregnancy complications in the future.
In the evolution of spontaneous
decidualization, the decidualization
process becomes independent of the
actual initiation of pregnancy.Nevertheless, it is uncontroversial that
the process of spontaneous decidualiza-
tion is homologous to the process of
embryo-induced decidualization as the
former evolved from the latter.40 The
only difference is the mode in which the
decidualization is triggered, either by
maternal hormones as in spontaneous
decidualization (as in women) or by the
embryo as in induced decidualization (as
in the mice or rodents). This is the
reason why experimental work on mice
is a valid approach toward understand-
ing human decidualization even though
the mode of decidualization is different
between these two species.
At the end of the ovarian cycle,
menstruation is caused by the withdrawal
of the supportive function of progester-
one for the decidua. As a consequence,
menstruation has substantial mechanistic
similarities with the processes that initiate
labor.66 Birth is also associated either withMONTH 2020a systemic progesterone withdrawal
through the degeneration of the corpus
luteum (luteolysis) or by functional pro-
gesterone withdrawal caused by inhibi-
tion of progesterone signaling.67,68
Hence, it is likely that the mechanisms
deployed in the uterus during menstrua-
tion are homologous to those during
parturition.66 If in fact menstruation and
the uterine manifestations of parturition
are homologous, it is likely that defects
that affect the maintenance pregnancy or
the initiation of parturition could also
manifest themselves as aberrations in
menstruation. Pavlicev and Norwitz66
therefore suggest that substantial
research effort should be dedicated to-
ward testing whether biomarkers
expressed during menstruation are asso-
ciated with pregnancy complications that
could be useful as preconception diag-
nosis of likely pregnancy complications.
3. Menstruation in Humans
3A. Menstruation and abnormal
uterine bleeding
Hilary O.D. Critchley, MD; Jacqueline A.
Maybin, PhD.
I. The impact of menstrual bleeding com-
plaints. Understanding the mechanisms
underpinning the pivotal human event
of menstruation is critical to our un-
derstanding of AUB. AUB, which in-
cludes the symptom of HMB,3 is a
chronic complaint that affects the quality
of life and well-being of 1 in 4 women of
reproductive age (Figure 4).69 Previ-
ously, women experienced menstruation
approximately 40 times owing to preg-
nancy and lactation amenorrhea,
whereas in developed economies today,
women can expect up to 400 menses in
their lifetime.70 Therefore, AUB is
becoming more common and problem-
atic for women and society. In contem-
porary society, women are delaying
having children for a variety of reasons
such as personal choice, prioritization of
career, and other factors that impose a
delay in childbearing. Therefore, these
women wish to preserve their uterus
alongside their fertility. As a conse-
quence, surgical options are not always
appropriate because these end fertility
and may also involve higher risks thanAmerican Journal of Obstetrics& Gynecology 9
FIGURE 5
The PALM-COEIN classification for abnormal uterine bleeding in the
reproductive years illustrating the structural (PALM) and nonstructural
causes (COEIN) and as described in Munro et al3,73
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recent systematic review relevant to the
United States, it was conservatively esti-
mated that annual direct and indirect
economic costs of menstrual bleeding
complaints were in the order of $1
billion and $12 billion, respectively.71
Leiomyoma (uterine fibroids) are com-
mon, present in 70% to 80% of women
by the age of 50 years,72 and associated
with AUB or HMB. Among women in
their 30s and 40s, leiomyomas are often
the underlying cause of AUB, anemia,
and iron deficiency anemia. When the
presence of uterine fibroids is considered
along with complaints of AUB, the
annual estimated direct costs of this
complaint in the United States, when
surgery, hospital attendances, outpatient
visits, and prescribed medications are
taken into account, are as high as $4.1
billion to $9.4 billion. Furthermore, lost
work hours resulted in costs ranging
from $1.55 billion to $17.2 billion.71
II. A classification system for abnormal
uterine bleeding. To provide diagnostic
precision and specific treatment of AUB,10 American Journal of Obstetrics& Gynecologyclassification of causes of uterine
bleeding is crucial. The FIGO Menstrual
Disorders Committee has led on the
classification systems for causes of
chronic AUB in the reproductive
years.3,73 As alreadymentioned, there are
2 systems: the first system focuses on
terminology with an encouragement for
the removal of ill-defined terminologies
such as “menorrhagia” and “dysfunc-
tional uterine bleeding,” and the second
system focuses on the underlying causes
of AUB, using the acronym PALM-
COEIN3,73 for structural and nonstruc-
tural causes, respectively (Figure 5). It is
hoped that these 2 FIGO systems will be
used globally to improve the manage-
ment of women with AUB.
In the absence of any other features,
for example, leiomyoma or a coagulop-
athy,3 bleeding from the endometrium
may represent a “primary endometrial
disorder” (AUB-E). In the presence of
structural features such as leiomyoma,
polyp, and adenomyosis,3 it is not
known whether the presence of myo-
metrial structural entities such as AUB-L
(leiomyoma) or AUB-A (adenomyosis)MONTH 2020actually result in a “secondary endome-
trial disorder” (Figure 6). There remains
a true lack of knowledge about the
phenotype of the endometrium when
adenomyosis and leiomyomas are
present.
This exciting area merits substantial
research and many questions remain.
What is the aberration in women with
AUB-E? Do leiomyomas and adeno-
myosis contribute to the genesis of AUB
or HMB? If so, is it because they directly
affect the molecular mechanisms of
endometrial hemostasis? Do leiomyo-
mas actually need to be adjacent to the
endometrium to cause AUB?74 To
answer these important questions, we
need to fully understand endometrial
physiology and pathology.
III. Methods for the study of menstru-
ation. Identification of aberrations in
endometrial function necessitates study
of human endometrial tissue. Women
must have a detailed clinical history and
examination and undergo investigation
to determine if structural disorders are
present. For research purposes, women
should have measurement of their
menstrual blood loss to enable catego-
rization as having heavy or normal
menstrual bleeding. An objective mea-
surement of blood loss may be obtained
using the alkaline hematin method and
total menstrual volume by using a
menstrual cup.23,75 Alternatively, a
pictorial menstrual blood loss assess-
ment chart has been validated to assess
menstrual blood loss volume and dura-
tion.76 In addition, tissue must be care-
fully classified to determine the correct
stage of the menstrual cycle.
Studies in women are often limited to
generation of observational data. Formore
incisive functional studies, animal models
of simulated menstruation have been
developed.55,77e79 The nonhuman pri-
mate (rhesus macaque) has been studied
extensively and provides an excellent
model of the human menstrual cycle.80,81
More recently, attention has focused on
refinement of the mouse model of simu-
lated menstruation.55,57,77,79
A detailed study of the cellular and
histologic events occurring in the mouse
endometrium during simulated
FIGURE 6
Potential mechanisms of “primary” and “secondary” endometrial AUB
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As the corpus luteum regresses in the absence of pregnancy, progesterone levels fall. This occurs
irregularly in those with ovulatory or iatrogenic AUB. Progesterone withdrawal causes a local in-
flammatory response in the endometrium and may be increased in those with primary endometrial
AUB. An increase in vasoactive factors results in intense vasoconstriction of spiral arterioles to limit
blood loss; this may be decreased in primary endometrial AUB. Vasoconstriction may induce
transient tissue hypoxia and stabilization of HIF-1, the master regulator of the cellular response to
hypoxia, to coordinate endometrial repair. There is evidence that this is less intense in those with
endometrial AUB. Efficient hemostasis limits menstrual blood loss at menstruation and this is
defective in women with coagulopathy AUB. Structural and nonstructural pathologies have the
potential to disrupt endometrial physiology at menstruation, leading to abnormal uterine bleeding;
these mechanisms remain undefined.
AUB, abnormal uterine bleeding; HIF-1, hypoxia-inducible factor 1.
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recapitulate several of the local events
that occur in the human endometrium
at the time of menstruation, these being
apoptosis preceding cytokine and che-
mokine expression and extensive
neutrophil influx into the endome-
trium.82 There is an interesting recent
discovery of a previously unrecognized
menstruating rodent, the spiny mouse,
which may provide another tool in the
study of menstruation.41
The combination of observational
data generated from well-categorized
human endometrial tissue and mecha-
nistic studies in validated animal models
will facilitate definitive experiments todetermine menstrual physiology and
pathology.
IV. Initiation of menstruation. The hu-
man endometrium is a highly dynamic
multicellular structure. Its physiological
functions are preparation for implanta-
tion and, in the absence of pregnancy,
menstruation. The regulation of normal
menstruation is governed by sequential
exposure to circulating sex steroids, es-
trogen, and then estrogen and proges-
terone followed by corpus luteum
demise causing a fall in both circulating
estrogen and progesterone. Progesterone
withdrawal is the trigger for
menstruation.53,83MONTH 2020 AMenstruation involves a remarkable
sequence of endometrial cell prolifera-
tion, differentiation, shedding, and
regeneration that may occur as many as
400 times across the reproductive life
course.70 The mechanisms underpin-
ning menstruation still remain poorly
understood. There are crucial in-
teractions between the endocrine system
and the immune system.53,83 These
cellular interactions, which are depen-
dent on the menstrual cycle phase,
involve epithelial and stromal cells along
with an influx of innate immune cells
and differentiation of the endometrial
vasculature (spiral arterioles). The local
endometrial events at the time of menses
resemble those of an inflammatory
event. There is an increase in endome-
trial blood vessel permeability and
fragility, tissue breakdown, and an influx
of innate immune cells into the endo-
metrium, particularly neutrophils and
macrophages.82,84,85
V. Cessation of menstruation. The cessa-
tion of menstrual bleeding and endo-
metrial repair require 3 closely related
events: these being vasoconstriction of
the highly specialized spiral arterioles,
local endometrial hemostasis, and ree-
pithelialization of the injured endome-
trial mucosa (Figure 6). After
menstruation, the restoration of the
injured mucosal surface is a rapid event
and the role of endometrial stem cells is
addressed in the following contribution
concerning endometrial regeneration.
Endometrial repair of the denuded
epithelial surface after menstruation has
been described by Garry et al,86 using
hysteroscopy, histology, and scanning
electron microscopy. These imaging
techniques detail the temporal repair of
the epithelial surface, which occurs in a
piecemeal fashion adjacent to actively
menstruating tissue.86 The regulation of
this endometrial repair process is not
fully defined. There is a recent interesting
interpretation of the link between hu-
man menstruation and separation of the
placenta after delivery. Both are under-
pinned by progesterone withdrawal and
critically involve uterine spiral arterial
function.87merican Journal of Obstetrics& Gynecology 11
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impaired vascular differentiation caused
by impaired spiral arteriole maturation
has been described88e90 along with
exposure to an imbalance of locally
generated vasoconstrictors and
vasodilators.91e93 An increase in blood
vessel radius will affect the resistance to
blood flow (Poiseuille’s equation).91 The
pivotal role for vasoconstriction after
progesterone withdrawal was described
nearly 80 years ago.94 The study of
autologous transplants of rhesus ma-
caque endometrium into the anterior
chamber of the eye and visualization of
the events of menstruation through a
slit-lamp ophthalmoscope revealed
transient and intense vasoconstriction 4
to 24 hours before menstruation in
response to steroid withdrawal. Authors
proposed that this vasoconstriction was
consistent with local tissue hypoxia. The
presence and role of endometrial hyp-
oxia in the process of menstruation have
been debated. There is now experimental
support for a pivotal role for transient
physiological hypoxia because it has
been reported to occur in the menstru-
ating endometrium.58 The stabilization
of hypoxia-inducible factor 1 (HIF-1; a
marker for hypoxia) results in the gen-
eration of local repair factors to “heal”
the injured mucosal surface (menstru-
ating endometrium).58
Women with HMB have decreased
endometrial HIF-1a at the time of
menstruation, and these women also
experience prolonged menstrual
bleeding episodes. These observational
data have been recapitulated in a mouse
model of simulated menstruation in
which physiological endometrial hyp-
oxia is also reported to occur at the time
of endometrial bleeding.58
Fibrinolysis is an important compo-
nent of regulation of normal endome-
trial bleeding. The human endometrium
contains tissue plasminogen activator (t-
PA) and urokinase plasminogen acti-
vator (u-PA), along with plasminogen
activator inhibitor (PAI) (inhibits fibri-
nolytic activity) and the u-PA receptor.
Women complaining of HMB have
raised levels of t-PA activity on the sec-
ond day of bleeding when compared
with those with normal menstrual blood12 American Journal of Obstetrics& Gynecologyloss, consistent with an overactive fibri-
nolytic system.95,96 Tranexamic acid, a
popular nonhormonal treatment for
HMB in many countries, targets the
overactivation of the fibrinolytic system
with a reported 58% reduction in men-
strual blood loss.97
VI. Endometrial pathology in structural
abnormal uterine bleeding. In the pres-
ence of structural pathologies (AUB-P/
A/L), a secondary endometrial disorder
has been proposed (Figure 6). The cur-
rent literature presents lines of evidence
to support the concept that there may be
an element of resistance to normal
progesterone-regulated events.98,99 The
latter is based on descriptive data and
may certainly be implicated given the
often reported poor response to many
progestin-based therapies, for example,
the levonorgestrel-releasing intrauterine
system and oral, implant, or injectable
progestins.69
VII. Therapies targeting the progesterone
receptor. Progestins have long been used
to modulate endometrial bleeding either
through their action on ovarian function
or abolition of ovulation along with a
direct effect on the endometrium to
reduce bleeding. All progestins, when
delivered orally, systemically, or through
an intrauterine route, improve men-
strual experience in many women;
however, there remains a consistent 20%
who experience unscheduled endome-
trial bleeding and spotting. This is often
a reason for the discontinuation of use of
progestin therapies. The mechanisms
underpinning this unscheduled bleeding
still remain elusive despite studies
focusing on many candidate
pathways.100e104 To date, there has been
no reliable preventative intervention,
albeit there are strategies to stop or
reduce a heavy bleeding episode in users
of progestin-only preparations.105
Selective progesterone receptor mod-
ulators (SPRMs) reduced endometrial
bleeding in women with uterine leio-
myomas.106,107 SPRMs inhibit ovulation
in 90% of women and also affect the
endometrium and many women expe-
rience amenorrhea.108 The mechanisms
of action of SPRMs on the endometriumMONTH 2020in women with abnormal bleeding and
uterine leiomyoma still remain poorly
understood. SPRMs have an interesting
antiproliferative effect, and the study of
cell-to-cell interactions within the
endometrium in women exposed to this
class of drug is a current topic of inves-
tigation.109 SPRM administration is
associated with an unusual morphologic
effect on the endometrium known as
progesterone receptoreassociated
endometrial changes (PAECs). These
morphologic features are associated with
alterations in expression and localization
of sex steroid receptors.109e112 The fact
that circulating estradiol levels remain
consistently in midfollicular range has
raised concerns among clinicians about
the risks of hyperplasia and endometrial
cancer. However, no studies to date that
have explored in detail the endometrial
impact have reported increases in either
hyperplasia or endometrial cancer.113,114
Moreover, a recent systematic review
reporting the endometrial effects of
SPRM (ulipristal acetate [UPA]) use in
10 studies involving 1450 women sup-
ports the current view that PAEC is
essentially a benign endometrial
morphology that is reversible on
discontinuation of UPA use.115
VIII. Summary comment.Understanding
the pathology underlying AUB is essen-
tial to improve treatments for this com-
mon symptom that has a significant
negative impact on women and society.
Progesterone and progesterone receptor
interactions play essential roles in uter-
ine physiology and reproduction. Pro-
gesterone withdrawal remains the major
trigger for the onset of endometrial
bleeding. Menstruation itself involves
repeated episodes of physiological
“injury and repair” and a detailed
knowledge of endometrial function is
essential for understanding how distur-
bances in the endometrial function play
a role in AUB. A particular gap is the
understanding of endometrial function
in women with myometrial structural
features such as leiomyoma and adeno-
myosis and whether this represents a
“primary or secondary endometrial dis-
order.” There is without doubt utility
and validity of mouse models of
ajog.org Expert Reviewsimulated menstruation, particularly
when used alongside human studies.
Ligands for the progesterone receptor,
that is, progestins and SPRMs, may
reduce endometrial bleeding and
modulate endometrial form and func-
tion. Identification of novel targets for
the treatment of AUB is vital to address
the significant personal and societal
burden of this common disorder.
3B. Regeneration after menstruation—
the role of stem cells
Hugh S. Taylor, MD.
I. Introduction. In each monthly men-
strual cycle, the endometrium is
renewed from the basalis layer.116e118
This regenerative process recapitulates
some features of development and in-
cludes production of all components of
the endometrium, including glands,
stroma, vasculature, and an influx of
immune cells. The ability to rapidly and
repetitively regenerate this tissue is
fundamental to reproduction. There-
fore, it is not surprising that there exists a
population of cells that serve to replace
and maintain the endometrium despite
repetitive loss with menstruation.116e118
These stem cells maintain a reservoir of
regenerative cells while simultaneously
giving rise to more differentiated cells.
II. Endometrial stem cells. Early research
in stem cells centered on the hemato-
poietic system, because experimental
transplants to repopulate bone marrow
could be performed using tissue abla-
tion.119 These studies gave rise to the
concept that stem cells divide asym-
metrically, reproducing the stem cell and
giving rise to a more differentiated cell,
in contrast to the symmetrical division
observed in somatic cells.119 However,
translation of this asymmetrical division
concept to other tissues and organs has
recently become controversial because
tremendous plasticity in the fate of
epithelial cells in the intestine, liver, and
other organs is being uncovered.119
Although specific mechanisms remain
debated, stem cells throughout the body
maintain the pool of regenerative stem
cells for populating each tissue and or-
gan. Most tissues contain a collection ofstem and progenitor cells that replace
adult cells lost to age or damage. In many
organs, stem cells divide only under
unusual conditions such as in response
to injury. In other organs characterized
by rapid turnover, such as the gastroin-
testinal tract, stem cells regularly divide
to replace worn or damaged cells as part
of normal tissue homeostasis.119 In the
endometrium, the vast majority of cells
are lost every month, making the need
for frequent stem cell division more
acute and essential.
Totipotent, pluripotent, and multi-
potent stem cells give rise to many
different tissues, whereas tissue-specific
stem and progenitor cells give rise to a
limited set of differentiated cells in a
local environment. Tissue-specific stem
and progenitor cells may give rise to a
single cell type or several types of cells
that make up an individual organ. In the
endometrium, multiple lines of evidence
in mice and humans support the pres-
ence of a population of stem and pro-
genitors that give rise to stromal
fibroblasts and another population that
gives rise to epithelia. Much of the cur-
rent knowledge on endometrial stem
cells comes from the studies in mice,
where cell lineages can be traced using
molecular tags and reporters, but un-
derstanding of the human endometrium
is accelerating as more signatures of stem
and progenitor cells in other organs are
identified, investigated, and validated
in the endometrium.116e118,120,121
Although early and even more recent
studies in humans suggest that endo-
metrial stem and progenitor cells are
localized to the basalis layer,122e124 more
recent evidence of stem and progenitor
cell markers in the luminal region sug-
gests a more complex picture of wider
dispersal125 because they are in non-
menstruating species such as the
mouse.126 Moreover, recent studies us-
ing tracers in the mouse endometrium
have identified stem and progenitor cells
that give rise to both epithelial glandular
and luminal epithelial cells,126e128
whereas other tissue-resident stem and
progenitor cells give rise to stromal cells
in the mouse endometrium.128 It is
possible that there is a common stem cell
that gives rise first to stromal cells andMONTH 2020 Acan also differentiate into a distinct
bipotential epithelial progenitor cell, as
suggested by studies in mice showing
gene expression evidence of
mesenchymal-epithelial transitions
(METs)57 and morphologic evidence of
such METs in humans.129 These tissue-
resident stem and progenitor cells
regenerate the endometrium after
menstruation in each menstrual cycle.
III. Bone marrowederived stem cells. -
There also exist multipotent stem cells in
several tissues that can divide and
differentiate into multiple types of cells
and are found in many tissue types. Most
notably, bone marrow hosts both he-
matopoietic stem cells, which give rise to
circulating white blood cells, red blood
cells, and platelets, and mesenchymal
stem cells, which give rise to bone,
cartilage, and fat.130 Bone marrow he-
matopoietic andmesenchymal stem cells
are found in the circulation, where they
can be recruited to sites of injury and
contribute to tissue repair in ways that
are still incompletely understood in
humans.131e133 In human patients who
received bone marrow transplants,
allowing donor cells to be tracked
through sex chromosomes or human
leukocyte antigen type, early studies
reporting that bone marrow cells differ-
entiated into hepatocytes or other
epithelial tissue types are now mostly
attributed to cell fusion or artifactual
protocols.133 However, bone marrow
fusion to endometrial stromal cells has
been characterized in mice and is rare
compared with bone marrow cells
directly contributing to endometrial cell
fates.134 Although the ability of mesen-
chymal stem cells to transdifferentiate
broadly into cells in other tissue types
remains controversial,135 convincing
evidence from human studies using
single-cell sequencing indicates that
bone marrowederived donor cells
differentiate into mature adipocytes—a
known cell fate for mesenchymal stem
cells.136 Studies in mice and humans
support the idea that bone
marrowederived stem and progenitor
cells also contribute to the reproductive
tract, supplementing the resident stem
and progenitor cells. In both the mousemerican Journal of Obstetrics& Gynecology 13
Expert Review ajog.orgmodel and in humans, bone
marrowederived cells are incorporated
into the endometrium where they
differentiate into endometrial stromal
cells, epithelial cells, and endothelial
cells.137,138 The vast majority of bone
marrowederived endometrial cells are
stromal cells with epithelial cells differ-
entiating slowly and in smaller numbers.
Other groups have subsequently
confirmed a bone marrow origin for
endothelial cells in the human139 and for
stromal and epithelial cells in
mouse,140,141 establishing a potential
role of bone marrow in endometrial
repair in humans and prompting human
clinical studies aimed at treating endo-
metrial disorders.118 Perhaps because of
the depletion after menstruation, exog-
enous stem cells may be even more
essential in the uterus than in other or-
gans. Furthermore, increased recruit-
ment and engraftment of these cells to
the uterus occur in response to injury
such as hypoxia or inflammation to aid
in repair and regeneration.142
IV. Consequences of stem and progenitor
cell loss. Infection and iatrogenic trauma
can lead to endometrial destruction and
loss of progenitor cells, causing failure to
regenerate lost tissue and resulting in
permanent damage. Multipotent stem
cells circulate to the endometrium and
engraft, contributing to the regeneration
of damaged endometrium and miti-
gating endometrial atrophy, thin endo-
metrium, and Asherman’s
syndrome.143,144 However, these circu-
lating bone marrowederived stem cells
are found in only very limited numbers
in the circulation. In the setting of severe
injury, the number of stem cells may
prove insufficient to repair the damage.
We have shown that augmented
numbers of bone marrow cells in the
circulation can prevent injury to
damaged tissue including the endome-
trium. Transfer of bone marrow cells to
mice after endometrial injury led to
subsequently normal fertility, whereas
those receiving placebo had severe
infertility because of Asherman’s syn-
drome. Several case reports and non-
randomized trials have explored delivery14 American Journal of Obstetrics& Gynecologyof endometrial stem cells to womenwith
inadequate endometrial development or
Asherman’s syndrome with promising
results for this potential novel ther-
apy.145,146 Understanding normal
menstruation and endometrial repair
may provide insight into several endo-
metrial pathologies.
We also found that the chemokine
CXCL12 attracts bone
marrowederived mesenchymal stem
cells to the endometrium.147 In a
mouse model, we found that the
administration of CXCL12 to the
damaged uterus can mobilize and re-
cruit stem cells from the bone marrow
to the uterus. In a mouse model of
Asherman’s syndrome, intrauterine
administration of CXCL12 led to
restoration of normal fertility.148,149
Similarly, in a mouse model of thin
endometrium, treatment with either
bone marrow supplementation or
CXCL12 administration restores
normal endometrial architecture and
fertility.144 Future therapy for Asher-
man’s syndrome may make use of che-
mokines that mobilize and attract bone
marrow cells without the need for bone
marrow stem cell transplantation.
V. Menstruation and potential role of
endometrial stem cells in endome-
triosis. Although rapid endometrial
regeneration is essential for reproduc-
tion in menstruating species, one of the
adverse consequences of menstruation
and a rapidly regenerating endometrium
is endometriosis. Menstruation allows
for retrograde menstruation and the
possibility of ectopic implantation of
endometrial tissue. Continued men-
strual flow regularly feeds the endome-
triosis and allows for lesion expansion.
Retrograde menstruation of stem cells in
particular contributes to the lesions.150
Furthermore, bone marrow stem cells
contribute to the continued growth of
endometriosis lesions.138,151 Bone
marrowederived stem cells may be
responsible for those rare endometriosis
cases outside of the peritoneal cavity
such as endometriosis occasionally seen
in the lungs or brain. The very processes
designed to regenerate and repair theMONTH 2020endometrium after menstruation can
lead to disease. Here, the circulating stem
cells can even lead to endometriosis in
areas where endometrial cells cannot
reach even through retrograde
menstruation.
Although retrograde menstruation
is a well-established cause of endome-
triosis, in reality endometrial cell traf-
ficking is common; we have previously
shown that stem cells from endome-
triosis can be found in the circulation
in a mouse endometriosis model.152
Similarly, we have shown that endo-
metrial cells can be identified in very
small numbers in multiple organs not
typically associated with endometriosis
including the brain, lung, spleen, and
liver.153 This vast cell migration may
explain many of the systemic effects of
endometriosis. Women with this dis-
ease are more likely to have depression,
anxiety, autoimmune disease, and a
lower average body mass index.154 The
regenerative ability of endometrium
and use of circulating stem cells may
allow for regeneration after menstru-
ation and enhance fertility; however, it
may predispose menstruating animals
to endometriosis and associated dis-
ease. Endometriosis can be considered
a systemic disease in which widespread
cell trafficking contributes to the
pathophysiology.154
VI. Endometrium, stem cells, and preg-
nancy. Finally, endometrium has an
essential role in the establishment of
pregnancy. Indeed, many complications
throughout pregnancy have their origin
at the time of implantation.155 It is not
surprising that stem cells are an impor-
tant part of endometrial and decidual
function in pregnancy. We recently re-
ported that there is a major flux of bone
marrowederived stem cells to the uterus
in pregnancy.156 These cells differentiate
into endothelial cells and decidual cells
that have a functional role in pregnancy.
In a mouse model of infertility based on
an endometrial receptivity defect,
administration of normal bone marrow
can restore fertility and successful preg-
nancy in otherwise infertile animals.
This leads to the fascinating conclusion
ajog.org Expert Reviewthat some instances of infertility or
pregnancy loss may be caused by inade-
quate bone marrow rather than defects
in reproductive organs or gametes.
Indeed, one can now include the bone
marrow as a key reproductive organ!
VII. Beyond the uterus: menstrual
bloodederived stem cells in the context of
regenerative medicine. The fast, scarless
regenerative power of the endometrium,
along with the relatively easy access to
endometrial stem cells from menstrual
effluent (see section 4), has spurred ef-
forts to use menstrual bloodederived
endometrial stem and progenitor cells
therapeutically for a range of regenera-
tive medicine applications beyond those
in the uterus mentioned previ-
ously.157,158 Endometrial mesenchymal
stem and progenitor cells (MSCs)120,124
share many properties with mesen-
chymal stem cells derived from the bone
marrow, adipose tissue, and other sour-
ces.159 Similar to mesenchymal stem
cells from these other sources, they can
be readily expanded in culture, show
features of differentiation into the ca-
nonical mesenchymal stem cell connec-
tive tissues (bone, cartilage, and fat), and
produce a range of immunomodulating
cytokines, chemokines, and growth fac-
tors.157,159 Reports that mesenchymal
stem cells from endometrium and other
sources can transdifferentiate into a va-
riety of nonconnective tissues, including
liver, pancreatic beta cells, and hepato-
cytes, both in vitro and in animal models
or in studies of human bone marrow
transplant patients, have been attributed
to experimental artifacts, as described
previously and in section 4.
More than 1000 clinical trials
involving human mesenchymal stem
cells or their products are currently listed
on ClinicalTrials.gov as of May, 2020,
with many in advanced phase III stages
of testing. Of these trials, about 400 are
listed as involving autologous cells and
about 300 as involving allogeneic cells
(others do not specify in a searchable
term; they may involve cell products
such as matrix or exosomes). Clinical
applications listed on ClinicalTrials.gov
may broadly be divided into direct, per-
manent regeneration of connectivetissues (bone, cartilage, fat, or related
tissues), where autologous cells are
required, and immunomodulatory ap-
plications that tilt healing toward
regeneration rather than fibrotic repair
through transient action of the thera-
peutic cells. For example, a phase III
clinical trial is underway at the Cleveland
Clinic to treat Crohn’s disease fistulas with
allogeneic bone marrowederived mesen-
chymal stem cells after a successful phase
III trial outside the United States using
adipose-derived mesenchymal stem
cells.160 Similarly, advanced clinical trials
using allogeneic or autologous bone
marrowederived mesenchymal stem cells
to modulate inflammation are underway
for aplastic anemia,161,162 liver,163
lung,164,165 and many other acute or
chronic inflammation pathologies.
Of the mesenchymal stem cell clinical
trials listed on ClinicalTrials.gov, only 2
use menstrual bloodederived cells, both
taking place at Zhejiang University in
Hangzhou, China: 1 for chronic liver
disease166 and 1 for type 1 diabetes.
However, because menstrual
bloodederived mesenchymal stem cells
are an attractive source for autologous
transplant in regeneration of connective
tissues in women,157 especially consid-
ering that connective tissue cells exhibit
strong sex-based phenotypic differences,
several regenerative applications are
advancing through large animal studies.
Particularly promising is the potential
for endometrial mesenchymal stem cells
to repair pelvic organ prolapse by seed-
ing cells onto degradable scaffolds.158
These and other connective tissue ap-
plications are moving toward human
trials. Whether the ease of collection of
human menstrual effluentederived
stem cells, or performance factors of
these cells, will overcome the established
infrastructure that relies on bone
marrow, adipose tissue, and other sour-
ces for regenerative medicine or other
purposes is difficult to predict, but they
are in the running.
VIII. Conclusion. In summary, menstru-
ation in humans requires rapid regen-
eration of endometrium that is
facilitated by stem cells. Stem and pro-
genitor cells in the basalis layer are theMONTH 2020 Amajor source of new endometrium each
cycle. Bone marrow stem cells are
engaged to repair endometrium after
damage and are now known to be
functionally important for pregnancy in
mice.156 Stem cells play a crucial role in
reproduction. With this stem cells flux
comes the possibility of disease related to
aberrant endometrial growth, namely,
endometriosis. Endometriosis is a sys-
temic disease of inappropriate stem cell
differentiation. Menstruation is far more
complex than a simple loss of endome-
trium and regrowth—it requires con-
tributions from stem cells both within
the uterus and bone marrow. Menstru-
ation also predisposes to endometriosis,
which also involves far more than just
the immediate surroundings of the
uterus where most endometriosis settles.
3C. What does fibroid (leiomyoma)
research teach us about endometrial
function?
Elnur Babayev, MD; Serdar E. Bulun,
MD.
I. Pathophysiology of uterine fibroid
(leiomyoma) formation and growth.
Uterine fibroids are extremely com-
mon. More than half of women will
develop uterine fibroids by the age of 50
years.72 Patients present with AUB or
pressure symptoms such as pelvic
discomfort and pain, constipation, or
changes in urinary habits. Submucosal
fibroids are also associated with infer-
tility and early pregnancy loss.167e169
Fibroids are benign uterine tumors
characterized by disordered monoclonal
proliferation of uterine smooth muscle
cells embedded in an abundant extracel-
lular matrix. One proposed mechanism
of fibroid formation involves genetic and
epigenetic changes in multipotent stem
cells in the myometrium that lead to
abnormal proliferation and differentia-
tion. Physiological fluctuations in sex
steroid levels with subsequent growth and
involution of myometrial cells during the
menstrual cycle make these stem cells
vulnerable to mutations or epigenetic
changes and fibroid formation. The ge-
netic, epigenetic, molecular, and para-
crine mechanisms underlying fibroid
pathophysiology are highly diverse,merican Journal of Obstetrics& Gynecology 15
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individual tumors’ clinical behavior
(growing, stable, or regressing) and
response to medications.167,168
Fibroid growth is hormone depen-
dent, and the sex steroids estrogen and
progesterone are important regulators of
fibroid growth. Most fibroids decrease in
size after menopause, whereas preg-
nancy can lead to an increase in the size
of fibroids. Both systemic and local es-
trogen can stimulate fibroid growth, but
local estrogen production through aro-
matase activity in fibroid tissue seems to
play an important role in fibroid
pathophysiology.170e172 Estrogen in-
duces progesterone receptor expression
and progesterone responsiveness of the
tumor. Progesterone has been shown to
be essential for fibroid growth in animal
studies.173 Progesterone may regulate
fibroid growth indirectly through its
action on differentiated smooth muscle
cells, which in turn secrete paracrine
molecules that stimulate proliferation of
multipotent stem cells.174,175
II. The role of vasoactive substances and
inflammatory molecules in the pathogen-
esis of abnormal uterine bleeding second-
ary to fibroids. Fibroids may interfere
with normal endometrial function. In
fact, heavy menstrual or irregular
bleeding is the most common clinical
presentation of fibroids and can affect
the physical, social, and emotional well-
being of women. The degree of endo-
metrial dysfunction seems to be related
to the size and location of the fibroids.
Submucosal fibroids located immedi-
ately beneath the endometrium aremore
likely to disrupt endometrial integrity
and cause AUB. Subserosal fibroids are
less likely to do so. Intramural fibroids
represent an intermediate pathology,
although large intramural fibroids that
distort the endometrial cavity will likely
lead to abnormal menstruation.168,169
Dissecting the mechanisms of interac-
tion between fibroids and endometrium
can help us understand menstrual
biology andmay lead to the development
of novel therapeutic modalities for AUB.
Fibroids are space-occupying lesions
that, depending on their size, can place
significant mechanical stress on uterine16 American Journal of Obstetrics& Gynecologyarchitecture. Fibroids can increase the
amount of bleeding by simply increasing
the surface area of the endometrium. In
addition, changes in cell shape and
stretch can affect gene expression in the
myometrium and endometrium.176e178
Large intramural and submucosal fi-
broids may interfere with the myo-
metrial contractions that occur during
menstruation. These contractions help
to evacuate menstruation material from
the uterus and decrease blood loss from
endometrial vessels under physiological
conditions; thus, even a small submu-
cosal fibroid can lead to a significant
blood loss in these patients.167
Endothelin 1 (ET-1) is a vasocon-
strictor that affects spiral arterioles in the
endometrium53 and plays an important
role in myometrial contractility.179
Altered expression levels of ET-1 and
endothelin receptors (ETA-R and ETB-R)
in uterine fibroids may interfere with the
normal physiological function of the
myometrium during menstruation. Fi-
broids have higher levels of ETA-R and
lower levels of ETB-R than normal
myometrium.180,181 Thus, it may be
envisioned that altered endothelin
biology induced by a uterine fibroid may
affect the vascular function of the adja-
cent endometrium, giving rise to its
irregular development or shedding.
Menstruating endometrium is rich in
cytokines and prostaglandins. How this
inflammatory milieu affects fibroids and
vice versa is an active area of investiga-
tion. The composition of inflammatory
cells is different in areas of the endo-
metrium that overlay fibroids compared
with distant sites. Perifibroid endome-
trium has increased numbers of macro-
phages in all phases of menstrual cycle;
however, the number of uterine natural
killer (uNK) cells is decreased in the
secretory phase.182 Prostaglandin F2a
levels are increased in fibroid uteri,
which may explain the disordered
contractility and increased blood loss
observed in these patients. Moreover,
prostaglandin E2 (PGE2), which is pro-
duced in the normal menstruating
uterus, affects leiomyoma (fibroid) cells.
Normal myometrial cells do not show
any changes in gene expression in
response to PGE2, whereas leiomyomaMONTH 2020(fibroid) cells demonstrate increased
expression of antiapoptotic micro-
RNAs.183 Celecoxib, a cyclooxygenase 2
inhibitor, reduces the proliferation rate
of leiomyomas (fibroids) through a nu-
clear factor kBemediated decrease in
expression of cytokines and growth fac-
tors.184 Our understanding of the role of
prostaglandins in fibroid pathogenesis
may lead to new therapeutic approaches.
Gene expression analysis of endometrial
biopsies fromwomenwithHMBhas also
indicated differential expression of an-
tigen processing pathway genes in
women with and without fibroids.185
Thus, specific molecular pathways
might be responsible for abnormal
bleeding associated with fibroids.
III. Growth factors as primary mediators
of endometrial dysfunction in fibroid ute-
ri. Fibroid uteri demonstrate rich
vascularity and increased venous
plexus.168,169 There also seems to be
defective vasoconstriction as evidenced
by dilated venous spaces and vaso-
congestion. Increased angiogenesis is
also apparent in patients with fi-
broids,181,186 with altered expression of
angiogenic growth factors and their re-
ceptors. Variations in the number and
type of inflammatory cells, which pro-
duce angiogenic factors, in the endo-
metrium of fibroid uteri may contribute
to the differences in the expression of
these factors. Moreover, angiogenic
genes are differentially expressed in fi-
broids, myometrium immediately adja-
cent to fibroids, and distant
myometrium.168 Fibroids express
increased levels of the important angio-
genic molecule basic fibroblast growth
factor (bFGF) and endometrium asso-
ciated with fibroids demonstrates
increased expression of the bFGF re-
ceptor, bFGF receptor 1 (FGFR1).186
Increased activity of bFGF through its
receptor represents a possible patho-
physiological mechanism underlying
increased angiogenesis in fibroids, which
may ultimately contribute to HMB.
A paracrine interaction between fi-
broids and the endometrium exists that
is not just localized to the endometrium
overlying the fibroid; this interaction has
global effects on endometrial
ajog.org Expert Reviewfunction.187 For example, the Wnt/b-
catenin pathway plays an important role
in fibroid growth. Activation of this
pathway leads to increased expression of
transforming growth factor b3 (TGF-
b3), and fibroids demonstrate increased
expression of TGF-b3 compared with
normal myometrium. TGF-b3 stimu-
lates smooth muscle cell proliferation
and fibronectin expression.188Moreover,
TGF-b3 affects endometrial receptivity
and decidualization by altering the
expression of bone morphogenetic pro-
tein 2 receptors.189 This effect is likely
secondary to the decreased expression of
homeobox A10 (HOXA10). Removal of
intramural, but not submucosal, fibroids
seems to reverse the changes observed in
HOXA10 levels.190,191 Interestingly,
endometrium obtained from patients
with fibroids demonstrates decreased
levels of PAI-1 and thrombomodulin.
Endometrial stromal cells exposed to
TGF-b3 in vitro show decreased levels of
PAI-1, antithrombin III, and thrombo-
modulin.74 These experiments suggest
that fibroids affect menstruation by
altering homeostasis in the endome-
trium. Changes in clotting factor levels
may tip the balance toward anti-
coagulation, which may at least partially
account for the increased bleeding seen
in patients with fibroids.
Taken together, fibroids seem to cause
abnormal menstruation by interfering
with myometrial contractility, paracrine
signaling (growth factors, prostaglan-
dins, endothelin, angiogenic factors),
and hemostatic regulation (alteration in
the expression of clotting factors) in the
endometrium. Understanding the
mechanisms of AUB secondary to fi-
broids will shed light on these endome-
trial functions in normal menstruation
physiology and may lead to the devel-
opment of new therapeutics for women
with fibroids.
3D. Microbiome of the endometrium
Inmaculada Moreno, PhD; Iolanda
Garcia-Grau, MS; Carlos Simon, MD,
PhD.
I. Introduction. Humans have always
lived in a microorganism-colonized
world, in which microbes, especiallybacteria, exist in clear symbiosis with
humans. The concept of a human
microbiota refers to the sum of micro-
organisms that inhabit the human body,
and the number of commensal microbes
is estimated to be the same as the num-
ber of human cells.192 Human physi-
ology is influenced by the presence of
such microorganisms through the
expression of microbial genes (of which
there are several million in total in
contrast to only 23,000 human genes).193
Thus, the human microbiome is
considered our second genome and in-
teracts with the host genome creating
what is called a hologenome defining a
whole complex organism and contrib-
uting to genetic diversity.194 The balance
between host and bacterial cells has been
shaped through evolution, and the
microbiota in each body niche has adapted
in response to intrinsic (eg, host genetics)
and extrinsic or environmental factors (eg,
diet). This individual microbiota consti-
tutes a critical component of immunity,
and thus, colonization by different bacteria
may turn this mutualistic or commensal
interaction into a parasitic relationship,
predisposing the host to pathologic
conditions with variable severity of
symptoms.
II. Role of the microbiota in human health
and disease. The first evidence that mi-
crobes contribute to health and disease
comes from the 17th century when it was
shown that bacteria from different body
niches in the same individual are
different, and there are different bacte-
rial communities in the same body site in
healthy vs diseased subjects.195 It is now
apparent that microorganisms, specif-
ically bacteria, exert functional roles
in our body and communicate with
host cells by influencing metabolic
function, training of the host immune
system, and modulating drug in-
teractions.196 It is also known from
studies in mice and humans that the
profile of microorganisms inhabiting an
individual early in life contributes to
postnatal development and adulthood
by influencing metabolism, respiratory
function, bone growth, and
immunomodulation.197e200 Several
studies have revealed that the gutMONTH 2020 Amicrobiota also affects neuro-
development, thereby affecting an in-
dividual’s behavior and cognition and
susceptibility to mental disorders
through the gut-brain axis.201,202 More
recently, the gut microbiome has been
linked to the secretion of circulating es-
trogens, leading to the estrobolome
concept (Figure 7). Because estrogens are
implicated in numerous biological pro-
cesses, disequilibrium of the microbiota
may subsequently contribute to a large
variety of estrogen-modulated condi-
tions, including metabolic disorders (eg,
metabolic syndrome, obesity), alter-
ations of female reproductive function,
and diseases in women (eg, polycystic
ovary syndrome, endometriosis, endo-
metrial hyperplasia).203
III. The existence of an endometrial
microbiota.Molecular detection of bac-
terial communities through 16S rRNA
gene sequencing has shown that the
human microbiota is related to human
health and welfare, as symbiotic micro-
organisms colonize every human organ,
including the reproductive tissues.204 In
adult women, the vaginal microbiota
contributes to 9% of the total bacterial
load and is characterized by a high sta-
bility with low richness and diversity
indexes.205,206
Highly sensitive detection techniques,
for example, the latest sequencing tech-
nology applied to microbiology, permit
the study of microbial communities at
the molecular level, providing ecological
information about the microbiota of low
biomass samples that have traditionally
been considered sterile owing to the in-
efficiency of culture-dependent methods
for isolating some types of bacteria un-
der standard laboratory conditions.207 It
must be noted that low biomass samples
are susceptible to being masked by
background bacterial DNA contained in
laboratory reagents and equipment.208
For this reason, the analysis of such
samples requires extra caution during
handling and manipulation and the
simultaneous analysis of blank controls
for monitoring potential contamina-
tion.209 The endometrial microbiota is
considered a low biomass microbiota
because the total amount of bacteriamerican Journal of Obstetrics& Gynecology 17
FIGURE 7
The estrobolome plays a central role in health and disease through the gut microbiota-estrogen axis
Dysbiosis of gut microbiota may induce systemic inflammation and interferes with estrogen metabolism and receptor activation in estrogen-regulated
organs, influencing neurocognition, metabolism, and the onset of gynecologic diseases and infertility.
Reprinted from Baker et al.203
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
Expert Review ajog.orgcolonizing the uterine cavity is 102 to 104
times lower than the total bacterial load
in the vagina.210,211
The microbiota of the upper repro-
ductive tract was identified by studies
applying molecular techniques, such as
quantitative polymerase chain reaction
or parallel sequencing, to endometrial,
fallopian, and peritoneal samples (re-
view by Koedooder et al, 2019).21218 American Journal of Obstetrics& GynecologyRecently, the existence of a microbiota
continuum throughout the reproductive
tract has also been described. Lactoba-
cillus spp. are the most frequently iden-
tified bacteria in the lower reproductive
tract of asymptomatic reproductive-age
women, but the abundance and struc-
ture of the microbiota change progres-
sively toward the upper tract.211 To date,
several studies have analyzed theMONTH 2020composition of the endometrial micro-
biome of reproductive-age women using
culture-independent methods.
Comparative studies have reported that
the endometrial and vaginal microbiota
are similar but not identical in every
woman.210,213,214 Routes of endometrial
seeding have been proposed,212 with the
most likely route being the ascent of
bacteria from the vagina, as supported by
ajog.org Expert Reviewthe resemblance of the microbiota in
consecutive spatial niches and the iden-
tification of Gardnerella vaginalis bio-
films in the endometrial walls of women
with bacterial vaginosis (BV).215 Most
studies analyzing the endometrial
microbiota agree on reporting Lactoba-
cillus as the most common bacteria
detected in studies using culture-
independent techniques, whereas other
genera, from the Bifidobacteriaceae,
Comamonadaceae, and Streptococcaceae
families, are also commonly found in the
uterine cavity of healthy and fertile
women.211e213,216e220 However, a
recently published paper shows that
although 60% of the analyzed endome-
trial samples present a detectable micro-
biota compared with background
controls and different from that in the
vagina, rectum, and oral cavity, Lactoba-
cillus was rarely abundant in this type of
sample.221 Because each study used
different designs, types of samples, and
sequencing platforms, defining the core
endometrial microbiota is challenging;
no consensus has been reached so far
regarding the molecular signature of the
uterine cavity. In addition to the investi-
gation of the core endometrialmicrobiota
under physiological conditions, the role
of endometrial microbiota in the origin
and maintenance of several gynecologic
diseases, including pelvic inflammatory
disease, endometriosis, and cancer, is
currently under study.211,222e225
IV. The impact of the endometrial micro-
biome on reproductive health outcomes,
fertility, and pregnancy. Fertility prob-
lems can be related to microbial imbal-
ance in the reproductive tract. The
cervicovaginal microbiota of infertile
women is more diverse and has lower
levels of Lactobacilli (specifically Lacto-
bacillus iners) and higher levels of BV-
associated bacteria (Atopobium vaginae,
G vaginalis, Ureaplasma spp., Lepto-
trichia, Sneathia) than the microbiota of
fertile women.226e230 Moreover, the
abundance of Lactobacillus spp. in
vaginal and endometrial samples of
infertile patients undergoing assisted
reproductive technology (ART) is
significantly lower than that in samples
from fertile volunteers.217Pregnancy success is affected by the
endometrial microbiota as indicated by
conventional culture techniques
showing that isolation of bacterial
pathogens from the tip of catheters used
for embryo transfers associates with
poor reproductive outcomes,231e235 but
the effect of bacteria on human repro-
duction is not restricted to the uterine
cavity. Microbial culture of ovarian and
follicular fluid showed that isolation of
dysbiotic bacteria correlates with higher
embryo discard rates and adverse ART
success after in vitro fertilization (IVF),
whereas isolation of Lactobacillus spp.
associates with better pregnancy
outcomes.236
Our research group has used 16S rRNA
sequencing to prospectively investigate
the microbiota of endometrial fluid
samples collected from patients under-
going IVF with repeated implantation
failure in relation to their clinical results
after embryo transfer.213 Lactobacilluswas
more abundant in patients with success-
ful pregnancy compared with those with
cycle failure. Interestingly, high Lactoba-
cillus abundance in endometrial samples
was a significant variable for predicting
the reproductive success of the patients.
In contrast, low abundance of Lactobacilli
together with specific pathogens was
associated with poor reproductive out-
comes resulting in implantation failure,
biochemical pregnancy, or clinical
miscarriage.213
In addition, as an incidental finding,
we were able to compare, at the tax-
onomical and functional level, the hu-
man endometrial microbiota present in
a successful fourth-week pregnancy to
that of a previous eighth-week sponta-
neous clinical miscarriage in the same
patient with euploid embryos. Bacterial
diversity was lower and Lactobacillus
abundance higher (L iners was the only
bacterium found) during the healthy
pregnancy.237 These novel observations
may profoundly affect our understand-
ing and possible clinical translation of
the microbiome in relation to healthy or
pathologic human pregnancy.
V. Reproductive tract microbiome before,
during, and after reproductive age.Un-
derstanding endometrial microbiotaMONTH 2020 Afluctuations during the life cycle and in
response to different stimuli will help to
anticipate dysbiotic shifts from the
Lactobacillus-dominated physiological
state and will allow the design of novel
interventional strategies to restore the
endometrial microbial profile. However,
because sampling the endometrium is
invasive, longitudinal studies have not
yet been published describing the sta-
bility of the endometrial microbiota in
the life cycle of healthy, diseased, and
infertile subjects. In contrast, the mi-
crobial profile of the vagina, which is
easily sampled, has been temporally
analyzed. Estrogen levels are the most
critical variable driving vaginal micro-
biota changes occurring over a life span.
Estrogen modulates the availability of
glycogen in the vaginal epithelium and
the subsequent growth of Lactobacilli
(Figure 8).238 Because Lactobacillus spp.
produce lactic acid, the dominance of the
vaginal niche by Lactobacilli entails the
acidification of the niche (where Lacto-
bacillus have a growth advantage),
creating a hostile environment that im-
pedes the growth of pathogens.
In children, the vaginal microbiota is
mainly colonized by common aerobic
bacteria (ie, Enterobacteria, Strepto-
coccus, Staphylococcus) and other gram-
positive (ie, Actinomyces, Peptos-
treptococcus) and gram-negative (ie,
Veillonella, Bacteroides) anaerobes.
Interestingly, Lactobacillus, G vaginalis,
and Prevotella bivia, some of the most
representative reproductive tract bacte-
ria in adults, are absent from the vagina
during this period.239,240 Then, coin-
ciding with the estrogen rise at the onset
of puberty, the bacterial profile is
reshaped to resemble that of adult
women, with increased abundance of
Lactobacillus detected in premenarcheal
adolescents. After menarche, the vaginal
microbiota is definitively stabilized and
obtains the reproductive-age microbiota
profile with dominance of Lactobacillus
clusters in the majority of studied sub-
jects. Interestingly, G vaginalis levels also
rise during puberty in some subjects
even before their first sexual contact.241
The vaginal microbiome of healthy
women can be classified in different
community state types (CSTs) based onmerican Journal of Obstetrics& Gynecology 19
FIGURE 8
The vaginal microbiome during the life cycle
Bacterial populations inhabiting the vagina change in response to estrogen levels, modulating glycogen availability in the vaginal epithelium and
subsequently the growth of bacteria based on the physicochemical features of the niche at each phase of the lifecycle.
Reprinted from Muhleisen et al.254
Mod, moderate.
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Expert Review ajog.orgthe structure of bacteria identified. Four
CSTs are characterized by the dominance
of Lactobacillus spp., namely, Lactoba-
cillus crispatus (CST I), Lactobacillus
gasseri (CST II), L iners (CST III), and
Lactobacillus jensenii (CST V). These 4
clusters associate with vaginal health,
whereas a non-Lactobacilli microbiota
abundant in reproductive tract patho-
gens, such as G vaginalis, A vaginae,
Dialister, Megasphaera, Prevotella, and
Sneathia, is classified as CST IV and as-
sociates with BV.242
Colonization and maintenance of mi-
crobial populations in the vagina of20 American Journal of Obstetrics& Gynecologypremenopausal women may be affected
by many factors (eg, age, hormonal
milieu, hygiene, menstruation, use of
contraceptives, sexual activity, ethnicity),
leading to potential CST shifts over short
periods of time or even within 1 men-
strual cycle.242e244 During pregnancy, the
richness and diversity of the vaginal
microbiota tend to decrease, accompa-
nied by increased Lactobacillus, which is
consistent with higher levels of
estrogens.245e248 However, dominance of
vaginal microbiota by G vaginalis, Ure-
aplasma, Prevotella, or other pathogenic
taxa during pregnancy associates withMONTH 2020complications, mainly preterm
birth.249e251 After delivery, vaginal bacte-
rial diversity increases and may generally
shift toCST IV for up to 1 year postpartum
even for women with high Lactobacillus
abundance during pregnancy.248
During menopause, estrogen levels
drop, and Lactobacillus spp. levels fall to
become 10- to 100-fold less than in
premenopausal women. This occurs
with a concomitant increase in Pre-
votella, Gardnerella, Atopobium, Ure-
aplasma, and anaerobic bacteria
belonging to CST IV. Interestingly,
postmenopausal women receiving
ajog.org Expert Reviewhormone replacement therapy have
levels of Lactobacillus similar to those
observed before the menopause.252e254
VI. Influence of menstruation on the
reproductive tract microbiota.Hormonal
changes within the menstrual cycle are
proposed major regulators of the
reproductive tract microbiota. During
the menstrual cycle, circulating estro-
gens and progesterone positively corre-
late with community constancy, whereas
during menses, the microbiota is more
prone to bacterial changes.243 There are
different community trends during the
menstrual cycle with some communities
remaining stable across the whole cycle,
whereas others experience CST shifts in
response to menses243 and shift back
after menstruation. A stable pattern is
observed in some women colonized by L
crispatus,255 whereas the majority of
women undergo microbial population
changes with menses, entailing transi-
tions from microbiota dominated by
Lactobacillus to microbiota with L iners,
G vaginalis, gram-positive cocci, or other
dysbiotic bacteria.256,257
L iners and G vaginalis levels may rise
in the vagina during menses because of
their capacity to grow under adverse
conditions. For example, G vaginalis
cannot grow in iron-limiting conditions
but is able to secrete vaginolysin to lyse
host cells (ie, erythrocytes) to gather
iron. In addition, some Lactobacillus
strains have protective mechanisms
enabling them to grow in the presence of
iron. For example, L crispatus encodes an
iron transport system. Similarly, L iners
synthesizes a unique ironesulfur protein
cluster that confers the ability to
sequester iron from menstrual blood,
providing L iners with an advantage over
L gasseri and L jensenii, within the vaginal
niche during menses.255,258,259
At the functional level, fluctuations of
the cervicovaginal microbiota have been
associated with innate immunity, HIV
acquisition, inflammatory status, and
epithelial barrier function.260 For
example, women with G vaginalis
showed a sharper decrease of the
epithelial barrier protein repetin from
the ovulatory to the luteal phase than
women with a Lactobacillus-dominatedmicrobiota.260 However, no studies have
identified yet the relevance of the
microbiota for menstrual function or
ascertained if the observed changes are
driven by the cycling sex hormone levels,
the microbiota profile, other causing
agents, or a combination. To shed some
light on the role of bacterial taxa on
menstruation, a recent study has char-
acterized the endometrial and cervical
microbiota of women with AUB at
different phases of the menstrual cy-
cle.261 This study has revealed significant
differences in the endometrial micro-
biota between women presenting with
HMB and dysmenorrhea. Although the
endometrial samples of women with
dysmenorrhea presented an increased
abundance of Acinetobacter spp., facul-
tative anaerobic genera were increased in
endometrial samples of patients with
dysmenorrhea, suggesting a potential
contribution of microbial communities
to these menstrual symptoms, although
the cause-consequence analysis has yet
to be undertaken.261
VII. Mechanisms for bacterial-host inter-
action.How bacterial cells communicate
with their hosts is still under investiga-
tion, but several mechanisms have been
proposed. Bacteria can synthesize small
molecules (eg, short-chain fatty acids,
proteins, oligosaccharides, vitamins,
short noncoding RNAs, neurotransmit-
ters) that may interact with host cells in
several ways, including regulation of the
physicochemical conditions of a niche,
epigenetic regulation through proteins
interacting with the host transcriptional
machinery, or binding to host receptors
(see reviews207,262,263) (Figure 9). Of
note, amines produced by gut bacteria
can, owing to their chemical and struc-
tural similarity to human endogenous
ligands, effectively bind G
proteinecoupled receptors (GPCRs),
indicating how microbial metabolites
might regulate host functions.264 GPCRs
comprise the largest family of receptors
in humans and are responsible for a wide
variety of intracellular processes in
response to extracellular signals mainly
mediated by hormones, neurotransmit-
ters, or other stimuli. During reproduc-
tion, GPCRs are responsible forMONTH 2020 Aresponding to neuropeptides and essen-
tial hormones, such as gonadotropin-
releasing hormone (GnRH), luteinizing
hormone, follicle-stimulating hormone,
prostanoids, and others, in the
hypothalamus-pituitary-gonadal axis.265
This type of host-microbial interaction is
of outstanding relevance in pathologic
processes because GPCRs are pharma-
cologic targets of 35% of approved drugs,
and the composition of the microbiota
and its derived products could interfere
with drug efficacy. Conversely, up to 25%
of nonantibiotic pharmaceutical drugs
designed to target human cells, including
antidiabetics, antidepressants, antipsy-
chotics, and some anti-inflammatory
drugs, present antimicrobial activity or
alter the composition of the indigenous
microbiota, leading to potential side effects
and increasing resistance to antibiotics.202
VIII. Conclusion. The reproductive tract
microbiome is currently considered a
pivotal player inwomen’s health. Further
investigation of the underlying mecha-
nisms of host-bacterial interactions is
needed to better understand both phys-
iological and pathologic conditions.
Translational implementation of this
knowledge might allow us to shape the
microbiome to promote global health
using alternative methods and thereby
avoid antibiotic abuse.
4. Menstruation as an Investigative
Tool and Diagnostic Resource
Christine N. Metz, PhD; Ridhi Tariyal,
MBA, SM; Ji-Yong Julie Kim, PhD;
Aoife Kilcoyne, MBBCh, BAO; Peter K.
Gregersen, MD
I. Introduction
The process of menstruation produces a
natural tissue biopsy that is arguably
underappreciated as a potential source of
rich information on the health status of
the endometrium. Growing awareness
among patient populations about men-
strual disorders and the advances in
mHealth apps, data science, and the
ever-decreasing costs of sequencing are
driving new opportunities to charac-
terize normal and pathologic menstrual
functions. Interest in the endometrium
as a model of fast, scarless healing for american Journal of Obstetrics& Gynecology 21
FIGURE 9
Potential mechanisms of interaction between endometrial cells and the uterine microbiome
Reprinted from Baker et al.207
AMP, adenosine monophosphate; ROS, reactive oxygen species; SCFA, short-chain fatty acid; TLR, toll-like receptor.
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cations further motivates the study of
both normal and pathologic menstrual
shedding and regeneration, using both
analysis of shed menses and tissue engi-
neering approaches to capture complex
interactions among epithelia, stromal,
immune, and other cell types present in
the uterus. Complementing these ap-
proaches, insight into the behaviors of
the endometrium in the context of the
uterus in health and disease is achieved
with recent advances in imaging
technologies.22 American Journal of Obstetrics& GynecologyII. Using menstrual effluent to aid
diagnosis of menstruation-associated
conditions
Menstrual discharge contains shed
endometrium, comprising endometrial
epithelial cells, stromal cells, endothelial
cells, and other nonimmune and im-
mune cells together with microbial spe-
cies present in the uterus (see section 3D
on the microbiome) and vaginal tract
along with a vast array of proteins, RNA,
DNA, and metabolites. It is distinctly
different from peripheral blood, and its
composition aligns closely with that of
the endometrium.266 Because it isMONTH 2020considered a waste product discharged
from the body, the term “menstrual
effluent” has been used by some in-
vestigators (in 41 papers on PubMed as
of January 2020), whereas others refer to
the discharge as menses or menstrual
blood.
Menstrual effluent offers many ad-
vantages for investigating uterine health
compared with endometrial or uterine
tissues collected through surgical bi-
opsies, including noninvasive collection
methods, relatively large sample vol-
umes, and opportunities for repeat col-
lections (within and across cycles).
ajog.org Expert ReviewAlthough these advantages have been
recognized since menstrual cups first
became clinically available in the
1950s,267,268 menstrual effluent remains
surprisingly understudied, and until
recently, only a few sporadic attempts in
small-scale studies have been made to
relate properties of the menstrual
effluent to disease states or to use it for
disease diagnostics.269e280 Biochemi-
cally, in healthy women, menstrual
blood has been shown to have compa-
rable concentrations of steroid hor-
mones but higher prolactin levels when
compared with peripheral blood,269 and
proteomics analysis has revealed more
than 300 different proteins in menstrual
blood compared with peripheral
blood,275 including scores of proteins
and molecules involved in wound heal-
ing and regeneration.277 Small-scale in-
vestigations of platelets and coagulation
proteins in menstrual blood compared
with peripheral or uterine vein blood
have thus far given little insight into
potential causes of HMB but revealed
that menstrual blood platelets were
largely degranulated.270,271 At the
cellular level, in healthy women, small
studies showed that the NK cell reper-
toire in menstrual blood is stable over
many menstrual cycles and different
from peripheral blood,276 and menstrual
blood has relatively fewer CD16þ
monocytes and more NKT cells
compared with peripheral blood.266,279
Extending the immune cell analysis to
disease states, a small (38 patients) study
reported alterations in immune cell
populations in the menstrual blood of
women with fertility disorders.280 Viable
shed endometrial tissue collected from
menstrual cups has also been studied to
investigate the role of matrix metal-
loproteinases in endometriosis, although
again the studies were pilot in
nature.272e274
Several current forces support using
menstrual effluent for diagnostics.
Women are more comfortable with
various forms of hygiene products,
including menstrual cups, which are
becoming more mainstream for man-
aging menstruation, potentially allowing
for more reproducible collections. At the
same time, women are gravitatingtoward consumer health and digital
recruitment platforms, creating new
opportunities for research and diag-
nostic development.281,282 Greater
awareness of menstrual disorders and
gynecologic diseases is promoted by
widespread reporting of personal
suffering by celebrities, along with an
explosion of social media platforms
engaging patients, thus priming women
and adolescents to seek answers for
debilitating gynecology problems.
Finally, the growing awareness of the
shortcomings of blood-based bio-
markers in the diagnosis of complex,
chronic diseases is driving increased in-
terest in proximal tissueebased
approaches.283
Endometriosis affects 6% to 10% of
reproductive-age women and is esti-
mated to cost more than $20 billion per
year in the United States.284e287 Endo-
metriosis offers a particularly compel-
ling case for development of minimally
invasive menstrual effluentebased di-
agnostics. Endometriosis is character-
ized by lesions of endometrial-like
glands and stromal cells growing
outside of the uterus, which are often
associated with debilitating pain and
infertility.284,285,288 Although several
theories for its etiology involve devel-
opmental origins,289,290 Sampson’s
theory of reflux menstruation into the
peritoneal cavity remains a plausible
explanation in light of the clinical pre-
sentation observed in most cases of
endometriosis.
Numerous factors likely contribute to
a diagnostic delay for endometriosis of
up to 7 to 10 years.291e293 Some women
and adolescents experience vague
symptoms that overlap with other
conditions, whereas other women and
adolescents have few or no symptoms
and are not diagnosed until they present
with infertility. In addition, women
often experience minimization or
dismissal of pain symptoms, more
frequent misdiagnoses related to pain,
and gender-related disparities in the
treatment of pain when compared with
men.294,295 Although standard mag-
netic resonance imaging (MRI) or ul-
trasound imaging can suggest the
presence of endometriomas and aMONTH 2020 Alimited number of lesions in other lo-
cations, most patients display no
detectable lesions on imaging, thus
motivating more invasive investigation
of symptoms The definitive diagnosis of
endometriosis requires invasive surgery,
a procedure many women and adoles-
cents delay, avoid, or cannot afford.
None of the peripheral blood bio-
markers proposed for diagnosing
endometriosis exhibit the accuracy
required for clinical use.296
Menstrual effluent also offers a
particularly attractive noninvasive diag-
nostic for endometriosis because
numerous differences between the
eutopic endometrium in women with
endometriosis compared with unaf-
fected women have already been cata-
loged at the cellular and molecular level
based on analysis of biopsies.297e299
These characteristics prompted the
launch of a large-scale study to use cells
in menstrual effluent as a minimally
invasive diagnostic for endometriosis. To
date, more than 500 women, with and
without endometriosis, have been
recruited and enrolled through Research
OutSmarts Endometriosis (ROSE;
https://feinstein.northwell.edu/institutes-
researchers/institute-molecular-medicine/
robert-s-boas-center-for-genomics-and-
human-genetics/rose-research-outsmarts-
endometriosis) and the Genotype and
Phenotype Registry,300 respectively.
Women consented to provide samples of
menstrual effluent and access to their
medical records (including the pathol-
ogy reports documenting their diag-
nosis) and completed health or lifestyle
questionnaires. In early studies, women
provided menstrual effluent samples
using a reusable menstrual cup (pro-
vided by Diva International). Once
menstrual effluent collections and pro-
cessing methods were standardized, the
cellular composition of menstrual effluent
cells was profiled and the menstrual
effluentederived stromal fibroblast cells
were characterized to develop a noninva-
sive diagnostic for endometriosis.301
As found in previous studies, the
menstrual effluent in the ROSE study
was observed to be a complex, hetero-
geneous mixture of numerous cell pop-
ulations, with a predominance ofmerican Journal of Obstetrics& Gynecology 23
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cells.266,279,301 Although the sample size
in the initial published study is relatively
small (n¼14 controls and 6e8 endo-
metriosis subjects), menstrual effluent
samples from endometriosis subjects
were characterized by lower numbers of
uNK cells when compared with healthy
control subjects.301 Within the men-
strual effluent, stromal cells (comprising
<1% of cells) show numerous pheno-
typic and functional differences between
controls and patients with endometri-
osis,301 similar to those previously
described for stromal cells isolated from
endometrial biopsies.297,302e304 Addi-
tional results from examining the genetic
and functional characteristics of men-
strual bloodederived stromal cells sup-
port a dysregulated retinoic acid pathway
associated with endometriosis vs
controls.301
One of the major barriers of this study
was the inability to reliably collect
menstrual effluent from women with
pelvic pain using the menstrual cup. In
response to this challenge, a novel diag-
nostic menstrual collection sponge is
being developed for external use.
Although this external collection sponge
is still in development to maximize cell
yield and collection of noncellular con-
tent, the early experience has consider-
ably simplified menstrual effluent
collections from all populations,
including adolescents. Ongoing studies
are focusing on (1) refining assay
methods to quickly and noninvasively
diagnose endometriosis with reasonable
sensitivity and specificity, (2) imple-
menting a prospective study of women
who provide menstrual effluent samples
before diagnostic surgery and then sub-
sequently undergo laparoscopic surgery
to definitively diagnose endometriosis as
validation of the predictive power of this
diagnostic test, and (3) enrolling ado-
lescents (>9 years old) with symptoms
of endometriosis because this patient
group may greatly benefit from an early
diagnostic. If large enough samples sizes
are evaluated, results may identify diag-
nostic phenotypes or stratify endome-
triosis subtypes for treatment. Repeated
sampling of menstrual effluent may
allow treatment responses to be assessed,24 American Journal of Obstetrics& Gynecologyif correlates with treatment response can
be identified.
Collection and analysis of live cells in
menstrual effluent offer potential for
discrimination of patient subgroups
based on the analysis of cell identities
and phenotype responses to various
stimulations ex vivo that promote
decidualization, proliferation, or pro-
gesterone responsiveness that can
potentially provide insight into patient
responses to therapies. However, cell
isolation, characterization, and culture
are a resource-intensive approach,
similar to that employed for amniocen-
tesis or chronic villus sampling. This
method is feasible for research studies
but may be challenging to translate into
routine clinical practice. By contrast,
stabilization of the molecular constitu-
ents in menstrual effluent to allow
sample storage and batch processing
offers the possibility of lower-cost, high-
information content data regarding cell
types present through highly standard-
ized sequencing approaches. Genomic
sequencing data on well-controlled pa-
tient populations are rapidly becoming
available not only for the microbiome
(see section 3D) but also at single-cell
resolution of the endometrium charac-
terization for better disease
genotyping.305,306
To both take advantage of and
contribute to the increasing availability
of genomics data focus on the endome-
trial microenvironment, the company
NextGen Jane developed a Smart
Tampon system to provide facile access
to menstrual effluent for diagnostic
assessment of women’s reproductive
health using granular genomic analysis
and bioinformatic deconvolution. The
Smart Tampon may also be used on
nonbleeding days for sampling the
vaginal tract, allowing for a natural
enrichment of the various cell types
found in the reproductive tract,
depending on day of cycle (ovarian and
fallopian tube cells, cervical or endo-
metrial cells, and vaginal microbiome).
NextGen Jane studies found that
transcriptional analysis of menstrual
fluid has specific genomic characteristics
that are unique from cervicovaginal and
venous blood samples. Analysis ofMONTH 2020menstrual fluid has shown that the
genomic profile of menstrual blood
varies greatly by day of cycle, with nearly
800 genes that are differentially
expressed in menstrual blood on heavy
flow day (day 2) compared with venous
blood. Day 1 of the menstrual cycle
shows little variability to venous blood,
compared with day 2 where the greatest
differential expression may be observed.
In the future, it is hoped that the optimal
Smart Tampon will allow analysis of the
genetics, epigenetics, microbiome, and
transcriptome at scale. Methylation
sequencing, transcriptomics, small RNA
sequencing, microbiome analysis, and
exome sequencing can produce up to 35
gigabytes of data. This platform has the
potential to help fulfill the promise of
machine learning and precision medi-
cine for malignant and nonmalignant
conditions in women’s health.
Finally, analysis of menstrual effluent
at either cell or genomic levels offers
potential to improve clinical therapies by
pointing to new mechanisms that might
stratify patients into subgroups for
different therapies. In many cancers,
patients are stratified according to mo-
lecular markers that are related to the
disease mechanism, prognosis, and
response to therapy. For diseases as
common as endometriosis, adeno-
myosis, and others, it is likely that there
are subtypes of patients with different
molecular features that might respond to
different therapies.307,308 Compared
with cancer, where somatic mutations
guide targeted therapies, the molecular
features in endometriosis and adeno-
myosis are harder to identify because the
presence of somatic mutations is still not
well established.309 Menstrual effluent
provides both molecular and cellular
materials and, hence, may improve
diagnosis and patient stratification to-
ward a particular therapy.
III. Tissue engineering and
microfluidic approaches to study
menstruation phenomena
Paradoxically, one of the most well-
studied potential applications of men-
strual effluent over the past 30 years is as
a source of MSCs for various nonre-
productive tract tissue engineering
ajog.org Expert Reviewapplications. Although early reports that
endometrial MSCs could trans-
differentiate into insulin-producing is-
lets,310 cardiac tissue,311 and other
differentiated tissue have not borne out,
applications in reconstructing connec-
tive tissues in the reproductive tract still
hold promise.312,313 Tissue engineering
of the endometrium as a target of
learning about menstruation—defined
as growing three-dimensional (3D)
models with at least stromal and
epithelial cells present—has percolated
at a low level for decades, hindered in
part by the incredible difficulty in
expanding and cryopreserving human
primary endometrial epithelial cells
compared with the relative ease of
growing human primary endometrial
stromal cells (even from menstrual
effluent). The landscape changed
dramatically in 2017 with publication of
2 papers reporting robust expansion of
human primary endometrial epithelial
cells as organoids in basement mem-
brane Matrigel,314,315 using modifica-
tions of protocols established by the
Clevers group for expansion of human
intestinal epithelial cells.316 Recently,
scaffold-free endometrial organoids
comprising both epithelial and stromal
cells from endometrial tissue were
established, providing yet another 3D
model of the endometrium to study
important paracrine actions between 2
important cell types in response to
menstrual cycle hormones.317,318 These
protocols enable creation of tissue banks
comprising all the major endometrial
cell types and lay the foundation for an
explosion of activity in building models
of the menstrual cycle.
Efforts to grow the endometrium and
cells from the endometrium as a means
to investigate its pathophysiology date
back almost 100 years, with the earliest
efforts targeted at trying to understand
whether Sampson’s hypothesis for
retrograde menstruation as a cause for
endometriosis could be substantiated.319
The difficulty of growing epithelial
cells—they reportedly grew poorly un-
less stroma was abundant, and epithelial
cells grew as a sheet to cover the
explant—was noted in these early
explant cultures.319 The first 3Dcoculture of primary human endome-
trial epithelial and stromal cells,
comprising stroma embedded in a
collagen gel, overcoated with basement
membrane Matrigel seeded with
epithelia, resulted in awell-differentiated
confluent epithelial monolayer with a
basement membrane with ciliated
(luminal) and secretory epithelia and
was tailored to study blastocyst implan-
tation.320 This model, which re-
capitulates hormone receptor expression
and morphology, also revealed the
changes in uterine receptivity that
occurred with mifepristone compared
with levonorgestrel.321 An alternate
model employing decellularized human
endometrium reseeded with stromal
cells and epithelial glands showed hor-
mone responsiveness over a 28-day cycle
by secreting prolactin and IGFBP1, but it
was unclear whether a monolayer with
endometrial epithelial morphology was
achieved.322 The creation of multicel-
lular endometrial organoids with polar-
ized epithelial cells surrounding stromal
cells provided amodel to study paracrine
interactions between 2 important cell
types of the endometrium in response to
hormones.317,318 Although several im-
plantation and cell cross talk models
have been developed with endometrial
cell lines,323e327 the profound differ-
ences in production of cytokines and
growth factors by cell lines and primary
cells call into question the utility of such
models.328 However, a cell lineebased
model comprised of stromal cells
embedded in hormone cues: degrada-
tion and breakdown of tissue were
observed in response to the withdrawal
of decidual levels of progesterone.329 The
intricate cross talk between endometrial
stromal and epithelial cells in driving
hormone responses during menstrua-
tion has prompted efforts to create syn-
thetic extracellular matrices for the
coculture of endometrial stromal and
epithelial cells in 3D. These matrices
allow gentle dissolution of the extracel-
lular matrix to release local cytokines
and growth factors into the local peri-
cellular environment and formation of
confluent, stable epithelial monolayer in
coculture with an underlying
stroma.326,328 Although theseMONTH 2020 Aapproaches have not yet directly been
applied to menstrual tissues, they are
poised for this application.
A crucial missing element in 3D cul-
ture models of the endometrium needed
for menstruation is microvasculature,
which provides initial signals for
decidualization330 and regulates
oxygenation cues important for tissue
breakdown and repair.58 Such models
are on the horizon, as several micro-
fluidic culture models of microvascular
networks have been developed for
studies of immune cell-microvascular
interactions, tumor cell extravasation
and growth, and blood-brain
barrier.331e335 Recently, approaches to
using these models as foundations for
mucosal barriers have been described.
Apart from the intrinsic interest in
menstruation, the interest in endome-
trium as a model of fast scarless healing
and tissue repair277 has created mo-
mentum for applying these types of
models to menstruation, in hopes of
gaining broader insights into regenera-
tive processes.
Finally, microfluidic approaches allow
the integration of multiple so-called
“microphysiological systems” (MPSs)
or 3D models representing part of a tis-
sue or organ on a microscale. Integrated
systems allow the investigation of sys-
temic effects, including hormonal and
other factors that might influence
menstruation. An enabling technology
for such integration is a now-
commercialized onboard microfluidic
pump, first used to drive long-term
culture of 3D liver tissue336,337 and
adapted to study gut-liver in-
teractions338,339 and ultimately an inte-
grated platform supporting 10 different
interconnected MPSs communicating in
a common culture medium for a
month,340 including a 3D endome-
trium.328 This platform pumping tech-
nology was also adapted to build a model
of interconnected 3D units of ovarian,
fallopian, uterine, cervical, and liver tis-
sues integrated into a single communi-
cating fluidic system,341 allowing the
assessment of up to 5 different types of
tissues at a time over a menstrual cycle
mimic. These cultured MPSs are
responsive to ovarian hormones, andmerican Journal of Obstetrics& Gynecology 25
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hormones responses were amplified.341
As observed in other interacting-MPS
studies, paracrine actions between tis-
sues allowed the use of 1 universal me-
dium without compromising the
viability of the tissues during this study.
Microfluidic technologies are evolving
quickly as the need for user-friendly and
affordable systems becomes evident for
the research community. Microfluidics
will change the way in vitro studies are
conducted and will allow for new dis-
coveries that will deepen our under-
standing of uterine biology and
menstruation in a systematic way.
IV. Next-generation uterine imaging
Uterine imaging has been employed to
allow for noninvasive methods for
diagnosing women’s health symptoms.
Imaging may be used to noninvasively
assess conditions of pregnancy and as-
pects of uterine health and pelvic health,
including endometriosis.342e344
The indication for pelvic imaging
varies by patient age and clinical pre-
sentation. Common indications in pre-
menopausal patients include evaluation
for focal endometrial or myometrial le-
sions (eg, uterine leiomyoma [fibroids])
in patients with symptoms of AUB and
pelvic pain. In postmenopausal patients,
endometrial imaging is often performed
to evaluate the endometrium in patients
with postmenopausal bleeding.
Currently, diagnosis relies primarily
on anatomic imaging using both ultra-
sound and MRI that allows for direct
visualization of the endometrium, which
is complementary to the previously
described techniques, similarly nonin-
vasive, but allowing for direct visualiza-
tion of the endometrium in situ, rather
than sloughed endometrial tissue. Ul-
trasound and MRI may evaluate for the
presence of endometrial thickening and
the presence of focal endometrial lesions
or polyps. In the evaluation of suspected
endometriosis, transvaginal ultrasound
may be used to assess for deeply infil-
trating endometrial implants.345 MRI is
useful to map endometrial implants
throughout the pelvis, including extra-
uterine locations, and confers advan-
tages in terms of the larger field of view,26 American Journal of Obstetrics& Gynecologymultiplanar capabilities, and excellent
contrast resolution.346,347 A systematic
review and meta-analysis (based on the
results of 6 studies) compared the accu-
racy of transvaginal ultrasound with
MRI for diagnosing deep infiltrating
endometriosis.343 The detection of deep
infiltrating endometriosis by both MRI
and transvaginal ultrasound methods
indicated similar sensitivitiesebetween
0.59 and 0.85 depending on the site,
with greater sensitivity for detection in
the rectosigmoid segment over rec-
tovaginal, uterosacral, and rectovaginal
septum locations.343 The specificities of
MRI and transvaginal ultrasound were
similar and, similar to sensitivities,
showed a wide range depending on the
location.343 It is expected that imaging
methods will continue to improve and
are likely to be used in the diagnostic
workup for women experiencing symp-
toms of endometriosis.
Other potential future clinical appli-
cations of uterine imaging techniques
include early endometrial cancer detec-
tion, distinguishing between leiomyoma
and leiomyosarcoma, and assessing can-
cer response to treatment. Uterine and
pelvic imagingmay be combinedwith the
cellular and molecular assessment of
menstrual effluent to help aid in the
diagnosis of uterine pathology and for
improving the diagnosis of endometriosis
through noninvasive methods.
MRI and ultrasound are modalities
currently used for monitoring and pre-
dicting response to therapies offered to
reduce menstrual bleeding or achieve
amenorrhea before surgical interventions
for themanagement ofAUB. For example,
GnRH analogs are used to reduce leio-
myoma volume and perfusion. Contrast-
enhanced MRI is used clinically to assess
suitability of patients with uterine leio-
myoma for uterine artery embolization
and to indicate reductions in perfusion
after treatment.348 Applications of T2-
weighted MRI for estimation of uterine
and fibroid volume may be augmented
with dynamic contrast-enhanced (DCE)
MRI for the assessment of tissue perfusion
and permeability, and magnetization
transfer (MT) MRI to assess changes in
fibrosis and macromolecular content.
Such approaches have been exploredMONTH 2020extensively in other organs.349,350 There
has been limited application of DCE-MRI
andMT-MRI in the assessment of uterine
leiomyomas.DCE-MRI has been reported
to be sensitive to vascular changes
considered to accompany successful
GnRH analog treatment of leiomyo-
mas.351 Future development of MRI ca-
pabilities may offer complementary
noninvasive modes to assess treatment
responses for menstrual complaints.
Furthermore, evolving MRI techniques
during pregnancy that can track fetal
motion and evaluate glucose and oxygen
transport across the placenta may provide
anatomic and functional information
regarding placental health and fetal well-
being.352,353
V. Conclusion
The analysis of menstrual effluent in
combination with other new modalities
for the understanding of uterine biology
is in the very early stages of development.
It is highly likely that the application of
new technologies of genomic and
cellular analysis of menstrual effluent
and uterine tissues, including single-cell
approaches, will yield a deeper under-
standing of uterine pathophysiology and
new and less invasive methods of diag-
nosis, including developments for body
imaging. These new technologies may be
applied to a variety of uterine health and
female reproductive disorders, including
endometriosis, uterine leiomyoma, ade-
nomyosis, and uterine-factor infertility
and will thereby aid management stra-
tegies for the symptom of AUB.We hope
that these exciting scientific opportu-
nities will catalyze a new era of collabo-
rative investigation that will correct the
past deficit of attention to female
reproductive health and biology.
5. Addressing Menstruation Globally:
Progress and Gaps
Marni Sommer, DrPH, MSN; Sandy
Clark, MPA
I. Introduction
The global agenda to address menstrua-
tion, and specifically menstrual health
and hygiene, has gained significant mo-
mentum in recent years, ranging from
increasing investment in addressing the
ajog.org Expert Reviewmenstruation-related barriers girls in
schools in low- and middle-income
countries are facing to the more recent
“menstrual equity” and “period poverty”
movements spreading across high-
income countries. Although there is
growing recognition of menstruation as a
relevant issue within public health glob-
ally,354 there still exist many gaps in the
evidence for informing program and
policy. Reviewing how the menstruation
agenda has shifted in the last 15 years
provides useful insights into how efforts
have evolved and what remains to be
done.
II. Shift in menstrual agenda over the
last 15 years
In reviewing how the global menstrua-
tion agenda has evolved, we explore
shifts in the population of interest, the
research and programs underway, the
variation in activities by country income
status, and the milestones achieved.
There emerge from the analysis 5 periods
of time during which distinct efforts
were underway.
Earlier than 2004-2005
Before 2005, multiple efforts were un-
derway exploring or addressing
menstruation within global health. The
population of interest included adult
women of reproductive age, and in high-
income countries, an interest in the
declining age of menarche among girls.
Interventions addressing adult women’s
menstruation-related needs were pri-
marily within the clinical realm, such as a
focus on reproductive health and disor-
ders355,356 and the promotion of family
planning.357 Although the latter did not
address menstruation as a life course
issue, there was attention to the chal-
lenges of unscheduled, breakthrough
bleeding among other contributors to
contraceptive discontinuation.358. There
also existed a rich literature on
menstruation within the social sciences,
primarily derived from anthropologists
documenting menstrual traditions and
rituals, and its relationship to girls’ and
women’s roles within society. In the
1980s and 1990s, in high-income coun-
tries in particular, researchers explored
girls’ maturation experiences,359e361examining the psychological effects of
menarche, and the associations of early
menarche with girls’ engagement in
risky behaviors, such as increased
vulnerability to early sexual initia-
tion,362,363 depression,364,365 and sub-
stance use.366 Overall, the focus in high-
income countries remained on the in-
dividual and the clinical aspects of
menstruation.
In contrast, in low- and middle-
income countries, there began to
emerge a public health lens on menstru-
ation. Alongside the family planning
agenda, there were burgeoning efforts
within the water, sanitation, and hygiene
(WASH) field to address menstruation as
a challenge faced by girls in school.354
United Nations Children’s Fund (UNI-
CEF) hosted a roundtable event in Ox-
ford aimed at bringing attention to
“menstrual hygiene management”
(MHM), a newly coined concept focused
on addressing menstrual management
within WASH,367 and the Rockefeller
Foundation supported a series of case
studies on sexual maturation in schools in
Africa.368 In humanitarian contexts,
United Nations High Commissioner for
Refugees recognized the provision of san-
itary pads to refugees as part of one of its
core mandates,369,370 providing important
recognition of menstruation as a key
response aspect.
2005e2011. This window of time
brought an increased focus on girls as a
population of interest, with a growing
public health approach to menstruation
in low- and middle-income countries.
More specifically, important formative
research was conducted with girls in and
out of school, exploring their first men-
strual experiences, their levels and sour-
ces of knowledge about menstruation,
and how the onset of menstruation and
puberty might be influencing girls’
education.371e373 The studies, conducted
primarily in Africa and Asia, suggested
that many girls were experiencing their
first menstrual period with no previous
information or support, thus feeling
confusion, shame, and embarrassment
and, for some, a significant fear that they
were ill or dying.374,375 Multiple studies
highlighted ongoing taboos, restrictions,MONTH 2020 Aand stigma around menstruation and
how menstrual onset and its manage-
ment negatively affected girls’ abilities to
engage and participate in school.374,376,377
Social and physical barriers included, for
example, inadequate toilets, water and
disposal within school grounds, insuffi-
cient guidance and support around
managing their menstrual periods, and,
for some, a lack of effective menstrual
products and underwear.378,379 In
response, a number of interventions
emerged, such as the WASH in Schools
(WinS) agenda that focused on address-
ing MHM in schools,380 puberty books
developed for girls in low-income coun-
tries that included content on MHM,381
new social entrepreneurs developing
improved locally produced menstrual
products for girls,382,383 and public-
private partnerships by global sanitary
pad companies focused on improving ac-
cess to products.384
2012e2015.Over the next few years,
menstruation gained traction as a public
health issue for girls in particular.
Although in high-income countries it
remained within the clinical realm for
girls and women, in low- and middle-
income countries, research documenta-
tion of the MHM barriers faced by girls
continued, and pilot trials began to be
funded, primarily by the UK Govern-
ment Medical Research Council,
exploring MHM interventions for
adolescent girls in school.385,386 A pilot
trial in Kenya included, for example, the
provision of sanitary pads, menstrual
cups, and reproductive health informa-
tion, examining the impact on the rates
of sexually transmitted infections and on
reproductive tract infections (BV), un-
intended pregnancy, and school atten-
dance and performance.385 A case-
control study in India examined
women’s vulnerability to reproductive
tract infections in relation to the men-
strual cloths or products they used, with
the sample drawn from hospitals.387
Systematic reviews analyzed, for
example, the psychosocial and educa-
tional effects of addressing menstrua-
tion,388 and a small number of studies
explored the impact of early menarche
on rates of infection with herpes simplexmerican Journal of Obstetrics& Gynecology 27
BOX
Definition of MHM (JMP, 2012)
Women and adolescent girls are using a clean menstrual management material to absorb or collect menstrual blood, that can be changed in privacy
as often as necessary for the duration of a menstrual period, using soap and water for washing the body as required, and have access to facilities to
dispose of used menstrual management materials. They understand the basic facts linked to the menstrual cycle and how to manage it with dignity
and without discomfort or fear.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
Expert Review ajog.orgvirus and HIV and AIDS.389,390 These
growing efforts, particularly those
emerging from the water and sanitation
arena, contributed to a decision to
include MHM in the lobbying related to
the new sustainable development goals
(SDGs), with the aim of having targets
and indicators addressing MHM
included in the SDGs. This led to the
development of a formal definition for
MHM (Box).367
During this period, additional donors
began to support projects related to
MHM. The Canadian Government pro-
vided funding to UNICEF and the UN
Girls Education Initiative to partner with
Emory University on a 14-country WinS
for Girls project, which focused on con-
ducting formative MHM research and
developing intervention packages
addressing MHM in schools.380 The UK
government supported research on
MHM in emergencies, providing funds to
the International Federation of the Red
Cross to assess beneficiary preferences
around the types of menstrual products
(disposable vs reusable) in differing
emergency contexts.391 A new platform
arose for sharing learning with the
launching of an annual virtual conference
co-organized by the UNICEF and
Columbia University showcasing
research, practice, and policy onMHM in
schools.392 Funding from the Canadian
government also enabled the creation of
the “MHM in Ten” agenda led by the
UNICEFandColumbiaUniversity, which
brought togetherWASH, education, SRH,
gender, and adolescent health experts to
develop a 10-year agenda (2014e2024)
aimed at transforming schools for
menstruating girls.393 Additional social
entrepreneurs focused on developing
affordable menstrual products, and
advocacy campaigns grew around
“breaking the silence” on menstruation,28 American Journal of Obstetrics& Gynecologyincluding support forWASHUnited from
the Bill & Melinda Gates Foundation and
other donors to launch an annual global
Menstrual Hygiene Day on May 28.394
In addition, new publications began
to call attention to the overdue need to
explore additional ways in which
menstruation affects girls’ lives, such as
the need for data on the average age of
menarche in countries,395 the potential
for menarche to be a window of oppor-
tunity for engaging girls, their parents or
caregivers, and teachers on health as a
step toward subsequent conversations
on SRH, including family planning,396
and for women, their MHM experi-
ences in the workplace.397 A study con-
ducted in India explored associations
between the use and management of
menstrual cloths and disposal pads and
reproductive tract infections.387,398 The
first resource guidance on MHM, Men-
strual Hygiene Matters, was published
with support from the UK government
(DFID), recommending approaches for
addressing MHM in development and
emergency contexts,399 and UNESCO,
with support from Procter & Gamble,
published a puberty policy document
including attention to menstruation and
MHM as a key component of puberty
and comprehensive sexuality educa-
tion.400 There also emerged a stronger
articulation of menstruation as an issue
of health and human rights.401
2016e2018.During these years, there
has been an exponential growth in
attention to the menstruation agenda in
global health. This included increasing
resources and attention focused on
research and interventions in low- and
middle-income countries, along with a
growing awareness that high-income
countries were overdue to address the
menstruation-related needs of girls inMONTH 2020particular. The population of interest
expanded around the world, with an
ongoing focus on girls in and out of
school (ages 10e19 years) but growing
recognition that menstruation presents
challenges for women and all individuals
who menstruate, such as those with
differing gendered identities. The Bill &
Melinda Gates Foundation funded FSG
to conduct a global landscape in 2016,
An Opportunity to Address Menstrual
Health and Gender Equity, which exam-
ined the existing research links between
MH and broader health outcomes, social
norms, and education.402 The UK gov-
ernment (Enhanced Learning and
Research for Humanitarian Assistance
funding/DFID and Wellcome Trust)
supported the International Rescue
Committee and Columbia University to
build the evidence on MHM in hu-
manitarian contexts403 and develop the
MHM in Emergencies Toolkit; the latter
was launched in 2017, with 27 copub-
lishing humanitarian response organi-
zations. In 2018, United States Agency
for International Development
(USAID)/Office of Foreign Disaster
Assistance provided additional funding
to the joint team to focus on the men-
strual product disposal, waste manage-
ment, and laundering needs of displaced
populations with the aim of developing
additional evidence and a compendium
of practice. There also emerged a
growing social and mainstream media
attention. Newsweek and other major
outlets published significant stories on
menstruation, and the Period Poverty
and Menstrual Equity campaigns
emerged, focusing on removing taxes on
sanitary products.404 This growing
global movement also introduced new
conceptualizations and terminology in
relation to menstruation, which sought
to broaden the issue beyond that of the
ajog.org Expert Reviewfocus on water and sanitation, such as
menstrual health, menstrual health and
hygiene, and others. Medical Research
Council, DFID, and Wellcome Trust
Joint Global Health Trials have also
supported both feasibility pilot and full-
scale trial evaluating potential effect of
menstrual support on schoolgirls’ SRH
and schooling outcomes.385,386
Research, programming, and policy all
expanded during this period. A small
numberofpilot and full-scale quantitative
studies continued or were initiated in
Africa evaluating MHM interventions in
schools,375,385,405 with findings generated
on new measures for addressing
menstruation. Menstrual health policies
were drafted inmultiple countries, such as
India, Zambia, and Kenya,385,386,405,406
and in high-income countries, new
legislation began to emerge, such as the
Dignity Acts in the United States, which
improve access to menstrual products for
incarcerated individuals, and policies
focused on improving access to products
in homeless shelters and public
schools.407e409 Despite these important
legislative efforts, limited evidence exists
from the United States and other high-
income countries on the actual experi-
ences, including barriers faced, of man-
aging menstruation among girls and the
incarcerated and homeless individuals.
However, a small body of evidence is
emerging, particularly around the men-
strual management needs of low-income
populations in the United States.410 In
addition, this window of time brought an
explosion of attention to the provision of
menstrual products, with Grand Chal-
lenges Canada, the Case for Her, and
other donors supporting the scaling of
social entrepreneurial efforts in this arena
such asAfriPads, BeGirl, andothers411,412;
the launching of new global advocacy and
networking organizations, such as the
Menstrual Health Hub, the Menstrual
Health Alliance, and the UNFPA-
supported African Coalition on Men-
strual Health Management; and new
regional research capacity building initia-
tives, such as the UK Government Global
Challenges Research Fund supporting an
East African research group.385,386
Two challenges that remained
included the lack of support from sectorsbeyond WASH, including limited atten-
tion to menstruation and its relevancy
within SRH, education, gender, and
other key sectors, and the limited fund-
ing available for furthering the mea-
surement aspects of the menstruation-
related agenda that would enable
demonstration of the range of effects of
addressing menstruation.
2019 onward. Already in 2019, the evi-
dence base and action are growing, with
new publications examining what is
known about MHM among populations
with disabilities,413 proposed revisions
to the MHM definition to broaden the
concept and its measurement beyond the
original WASH origins,414 additional
systematic reviews,415,416 and ongoing
menstrual equity campaigns, global
advocacy, and intervention trials. In an
effort to move forward the existing
menstruation measurementerelated
challenges, including the lack of uptake
among other key sectors, a “Monitoring
Menstruation” meeting was hosted by
the Columbia University in March 2019
with support from the Water Supply and
Sanitation Collaborative Council that
brought together key global monitoring
and measurement experts from WASH,
gender, education, and health (sexual
and reproductive, psychosocial) to re-
view and find areas of alignment be-
tween the priority outcome and impact
measures of these sectoral areas with the
progress being made on menstrua-
tion.414 Importantly, USAID provided
new funding to explore and pilot in-
terventions addressing menstruation
and women’s economic empower-
ment.417 However, overall, resources still
remain limited globally to support sys-
tematic coverage of all menstruation
components, including access to infor-
mation, water and sanitation infra-
structure, supplies, and related clinical
aspects, such as engagement with
healthcare workers well trained on reg-
ular and irregular bleeding.
III. Evidence on menstruation globally
As described previously, the early years
of the menstruation agenda included the
use of primarily qualitative research
methods, given the need for formativeMONTH 2020 Aresearch on a sensitive topic about which
there was little documentation from a
public health perspective. In recent
years, there has been a shift toward
intervention trials, which have brought a
rigorous quantitative approach to
examining the impact of select
menstruation-related interventions for
girls in school in development contexts.
Research in emergency contexts has
primarily also been qualitative in nature,
including feasibility pilots of guidance
and programmatic response approaches.
Funding has remained limited for larger-
scale intervention trials that include
attention to water and sanitation in
schools, to longitudinal associations be-
tween inadequate and adequate atten-
tion to menstruation and SRH and
education outcomes, and to the rela-
tionship between menstruation and
women’s economic productivity and
empowerment in the workplace. In
addition, there has been a growth in
national-level data, such as the
PMA2020 national surveys incorpo-
rating questions around menstrual
management,418e420 and the inclusion
of questions on MHM within UNICEF’s
Multiple Indicator Cluster Surveys in
select countries.421 Finally, there exists
limited evidence on the menstruation-
related needs and experiences of girls
growing up today in high-income con-
texts and the MHM challenges faced by
low-income and other vulnerable pop-
ulations in such contexts.
IV. Status of menstruation-related
programming and policy
There exists a broad range of
menstruation-related programming
around the world. This includes, for
example, nongovernmental organiza-
tions providing sanitary products,
reproductive health or MHM informa-
tion, and improvement of water and
sanitation facilities in schools, both in
development and emergency contexts.
Many national governments, such as
South Africa, India, and Kenya, have also
begun subsidizing the provision of san-
itary pads (reusable and disposable) to
girls in school. In addition, new in-
novations are emerging in humanitarian
contexts, such as effort by Medicins Sansmerican Journal of Obstetrics& Gynecology 29
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16S rRNA gene: Encodes a component of the 30S small subunit of a prokaryotic ribosome. 16S rRNA gene sequencing is used for
phylogenetic studies because its presence is highly conserved among bacteria, but its sequence is species-specific.
Aromatase: An enzyme that transforms androgens into estrogens.
AUB: Abnormal uterine bleeding.
Biomass: Amount of living biological organisms in a given niche or ecosystem at a given time. The upper genital tract has a significantly lower
amount of bacterial DNA than other human microbiomes and is therefore considered a low biomass microbiota.
BMP-2: Bone morphogenetic protein 2.
COEIN: Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not otherwise classified.
Community state types (CST): Profile that defines the total bacterial community of a given body site based on the relative abundances of each
bacterium. The human vaginal microbial communities were classified into 5 groups. Specifically, CSTs I, II, III, and V are dominated by
L. crispatus, L. gasseri, L. iners, and L. jensenii, respectively, whereas CST IV has higher proportions of strictly anaerobic organisms.
DCE-MRI: Dynamic contrast enhanced-MRI.
Diversity (Beta diversity): Refers to the change in the number of taxa detected in 2 or more ecosystems. It is usually expressed as the total
number of species that are unique to each of the ecosystems being compared.
Dysbiosis: Shift in the physiologic microbiota resulting in an imbalance between commensal and pathogenic bacteria. Changes in microbial
composition owing to the gain or loss of the community members or changes in the relative abundance of microbes may contribute to the
initiation and/or persistence of many diseases.
Epigenetics: Heritable phenotype changes without changes in genotype (DNA).
Estrobolome: Represents the aggregate of enteric bacterial genes whose products are capable of metabolizing estrogens. Microbes in the
estrobolome produce beta-glucuronidase, an enzyme that deconjugates estrogens into their active forms, which are capable of binding to
estrogen receptors and influencing estrogen-dependent physiological processes.
FIGO: International Federation of Gynecology and Obstetrics.
GaP: Genotype and Phenotype Registry (registry of normal/control research subjects).
GnRH: Gonadotrophin releasing hormone.
Growth factor: A substance capable of stimulating cell growth, proliferation, and differentiation.
Gut-brain axis: Consists of bidirectional neural processing of information between the central nervous system and digestive system. Recent
research indicates that gut microbiota is a crucial part of the gut-brain network and communicates with the brain through the microbiota-gut-
brain axis.
HIF: Hypoxia inducible factor.
HMB: Heavy menstrual bleeding.
Hologenome: Theory that maintains that the physiology of any macroscopic organism derives from the integrated activities of the individual
genomes contributing to the organism (holobiont).
LNG-IUS: Levonorgestrel-releasing intrauterine system
ME: Menstrual effluent.
ME-SFCs: Menstrual effluent derived stromal fibroblast cells.
mHealth: Mobile health.
Microbiota and Microbiome: The human microbiota encompasses the group of microorganisms that live in association with the human body.
Conversely, the microbiome refers to the genes and genomes of this microbiota as well as their products within the host environment.
micro-RNA: Small noncoding RNA molecule regulating posttranscriptional gene expression.
MRI: Magnetic resonance imaging.
MSCs: Mesenchymal stem cells.
MT-MRI: Magnetization transfer-MRI.
Multipotent stem cell: A cell that can self-renew by division and can develop into multiple differentiated cell types.
Natural killer (NK) cell: A type of lymphocyte that can bind to certain tumor cells and virus-infected cells without the stimulation of antigens
and can kill them by the insertion of granules containing perforin.
PA: Plasminogen activator.
PAEC: Progesterone receptor-modulator-associated endometrial changes.
PAI: Plasminogen activator inhibitor.
PALM: Polyps, Adenomyosis, Leiomyoma, Malignancy.
Paracrine signaling: Signaling involving hormone that has an effect only in the vicinity of the cell secreting it.
PCOS: Polycystic ovary syndrome.
Richness (Alpha diversity): Refers to the diversity within a particular area or ecosystem. It is usually expressed by the number of species
(species richness) in a unique niche.
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ROSE: Research OutSmarts Endometriosis (research program dedicated to studying endometriosis).
SPRM: Selective progesterone receptor modulator.
TGF-b3: Transforming growth factor-beta 3.
T2W: T-2 weighted.
t-PA: Tissue plasminogen activator.
uNK cells: Uterine natural killer cells.
u-PA: Urokinase plasminogen activator.
ajog.org Expert ReviewFrontieres to build female-friendly
washrooms with disposal mechanisms
in the health clinics they run in the
refugee camps in Bangladesh hosting
Rohingya populations.422 Social entre-
preneurs, such as Days for Girls, Sus-
tainable Health Enterprises, BeGirl, and
AfriPads, continue to develop and eval-
uate the production and distribution of
menstrual products, ranging from reus-
able pads made by local populations to
period underwear.
As mentioned previously, there has
been a growth in menstrual policies
around the world. The Uganda National
Bureau of Standards passed one of the
first national standards for reusable
sanitary pads in Africa.423 A recent
analysis of the existing higher-level ed-
ucation policies in low-income countries
indicated that education sector plans and
policies still lack inclusion of attention to
menstruation and its proxies (such as the
provision of gender-segregated toilets),
which has implications for the inclusion
of budget line items to address the issue
in schools424; WASH in
Schoolsefocused menstrual policies
provide important guidance on what
interventions are needed but lack secto-
ral buy-in and financial support. The
Philippines provides an important
example with recent policy being incor-
porated into the country’s Education
Monitoring Information System,
providing local-level incentive to
include, for example, improved toilets in
schools and the provision of supplies of
sanitary pads for emergencies.425 How-
ever, as the “Monitoring Menstruation”
meeting held in Geneva in March 2019
indicated, menstruation has yet to be
taken up by other key sectoral pro-
gramming and policy, such as within
SRH, which could improve attention toanemia in adolescent girls, or the po-
tential for the onset of menstruation to
trigger child marriage.
V. Current and future pathways
Moving forward, there is much left to be
done, including addressing the
menstruation-related issues faced by all
those who menstruate, such as trans-
masculine and other populations; men-
strual barriers faced in workplace
contexts; recognition that more evidence
is needed on vaginal bleeding across the
life course, including the implications
for the provision of water, sanitation,
supplies, and access to healthcare and
information; improved engagement of
healthcare workers on the issue of
menstruation in low- and middle-
income countries in particular; the
important intersection of menstruation
and family planning; and improved
measures for monitoring and assessing
the impact of menstruation-focused in-
terventions along with cost-effectiveness
studies. Funding support has thus far
been limited for addressing this broad
spectrum of issues and for essential
intervention and measures-related work
that are needed to demonstrate critical
associations between menstruation and
population healthmore broadly. There is
an urgent need for a strong funding
stream to assure this impactful work can
be done. -
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